Mien-Chie Hung

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9248663/publications.pdf

Version: 2024-02-01

713	74,120	281	877
papers	citations	140 h-index	243 g-index

732	732	732	73891
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Tafenoquine and its derivatives as inhibitors for the severe acute respiratory syndrome coronavirus 2. Journal of Biological Chemistry, 2022, 298, 101658.	3.4	12
2	Development and validation of a radiopathomics model to predict pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a multicentre observational study. The Lancet Digital Health, 2022, 4, e8-e17.	12.3	91
3	Endothelial p130cas confers resistance to anti-angiogenesis therapy. Cell Reports, 2022, 38, 110301.	6.4	4
4	PARG inhibition limits HCC progression and potentiates the efficacy of immune checkpoint therapy. Journal of Hepatology, 2022, 77, 140-151.	3.7	20
5	Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics. Nature Reviews Clinical Oncology, 2022, 19, 287-305.	27.6	155
6	An optimized protocol for PD-L1 pathological assessment with patient sample deglycosylation to improve correlation with therapeutic response. STAR Protocols, 2022, 3, 101198.	1.2	2
7	Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer. Journal of Biological Chemistry, 2022, 298, 101817.	3.4	15
8	Phosphorylation and Stabilization of PD-L1 by CK2 Suppresses Dendritic Cell Function. Cancer Research, 2022, 82, 2185-2195.	0.9	15
9	Development and characterization of anti-galectin-9 antibodies that protect T cells from galectin-9-induced cell death. Journal of Biological Chemistry, 2022, 298, 101821.	3.4	16
10	Hereditary retinoblastoma iPSC model reveals aberrant spliceosome function driving bone malignancies. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2117857119.	7.1	13
11	De-glycosylated membrane PD-L1 in tumor tissues as a biomarker for responsiveness to atezolizumab (Tecentriq) in advanced breast cancer patients.. American Journal of Cancer Research, 2022, 12, 123-137.	1.4	1
12	MRNIP condensates promote DNA double-strand break sensing and end resection. Nature Communications, 2022, 13, 2638.	12.8	17
13	Prospects of the potential strategies to improve the efficacy of antiâ€PDâ€1/PDâ€L1 therapy. Clinical and Translational Medicine, 2022, 12, e803.	4.0	4
14	Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates.. American Journal of Cancer Research, 2022, 12, 1671-1685.	1.4	0
15	ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer. Science Immunology, 2022, 7, .	11.9	52
16	TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. Modern Pathology, 2021, 34, 710-719.	5.5	90
17	Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma. Journal of Hepatology, 2021, 74, 907-918.	3.7	14
18	The Beneficial Role of Sunitinib in Tumor Immune Surveillance by Regulating Tumor PDâ€L1. Advanced Science, 2021, 8, 2001596.	11.2	34

#	Article	IF	Citations
19	Cigarette smoke-induced LKB1/AMPK pathway deficiency reduces EGFR TKI sensitivity in NSCLC. Oncogene, 2021, 40, 1162-1175.	5.9	20
20	Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nature Communications, 2021, 12, 832.	12.8	248
21	TYRO3 induces antiâ€“PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis. Journal of Clinical Investigation, 2021, 131, .	8.2	135
22	Scutellaria barbata D. Don Inhibits the Main Proteases (Mpro and TMPRSS2) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. Viruses, 2021, 13, 826.	3.3	20
23	Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation. Nature Communications, 2021, 12, 2788.	12.8	11
24	Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer. Oncogene, 2021, 40, 4992-5001.	5.9	68
25	PKCÎ´-mediated SGLT1 upregulation confers the acquired resistance of NSCLC to EGFR TKIs. Oncogene, 2021, 40, 4796-4808.	5.9	9
26	Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade. Molecular Cell, 2021, 81, 2317-2331.e6.	9.7	97
27	Imatinib (STI571) Inhibits the Expression of Angiotensin-Converting Enzyme 2 and Cell Entry of the SARS-CoV-2-Derived Pseudotyped Viral Particles. International Journal of Molecular Sciences, 2021, 22, 6938.	4.1	7
28	The N-linked glycosylations of TIGIT Asn32 and Asn101 facilitate PVR/TIGIT interaction. Biochemical and Biophysical Research Communications, 2021, 562, 9-14.	2.1	3
29	A noncoding RNA modulator potentiates phenylalanine metabolism in mice. Science, 2021, 373, 662-673.	12.6	42
30	AMBRA1 Promotes TGFÎ² Signaling via Nonproteolytic Polyubiquitylation of Smad4. Cancer Research, 2021, 81, 5007-5020.	0.9	8
31	Functional significance of gain-of-function H19 lncRNA in skeletal muscle differentiation and anti-obesity effects. Genome Medicine, 2021, 13, 137.	8.2	8
32	Evading immune surveillance via tyrosine phosphorylation of nuclear PCNA. Cell Reports, 2021, 36, 109537.	6.4	6
33	Molecular mechanisms and functions of pyroptosis in inflammation and antitumor immunity. Molecular Cell, 2021, 81, 4579-4590.	9.7	127
34	RGS2-mediated translational control mediates cancer cell dormancy and tumor relapse. Journal of Clinical Investigation, 2021, 131, .	8.2	23
35	PRMT1 enhances oncogenic arginine methylation of NONO in colorectal cancer. Oncogene, 2021, 40, 1375-1389.	5.9	44
36	Nuclear translocation of the receptor tyrosine kinase c-MET reduces the treatment efficacies of olaparib and gemcitabine in pancreatic ductal adenocarcinoma cells. American Journal of Cancer Research, 2021, 11, 236-250.	1.4	2

#	Article	IF	Citations
37	Glycosylation of Siglec15 promotes immunoescape and tumor growth. American Journal of Cancer Research, 2021, 11, 2291-2302.	1.4	0
38	NONO phase separation enhances DNA damage repair by accelerating nuclear EGFR-induced DNA-PK activation. American Journal of Cancer Research, 2021, 11, 2838-2852.	1.4	0
39	Multi-organ metastasis as destination for breast cancer cells guided by biomechanical architecture. American Journal of Cancer Research, 2021, 11, 2537-2567.	1.4	1
40	Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance. Nature Communications, 2021, 12, 7041.	12.8	43
41	Ferroptosis: a promising target for cancer immunotherapy.. American Journal of Cancer Research, 2021, 11, 5856-5863.	1.4	1
42	Therapeutic targeting of the PI4K2A/PKR lysosome network is critical for misfolded protein clearance and survival in cancer cells. Oncogene, 2020, 39, 801-813.	5.9	16
43	A chiralityâ€dependent action of vitamin C in suppressing Kirsten rat sarcoma mutant tumor growth by the oxidative combination: Rationale for cancer therapeutics. International Journal of Cancer, 2020, 146, 2822-2828.	5.1	9
44	Musashi-1 promotes stress-induced tumor progression through recruitment of AGO2. Theranostics, 2020, 10, 201-217.	10.0	13
45	New Approaches on Cancer Immunotherapy. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a036863.	6.2	17
46	PP2A Deficiency Enhances Carcinogenesis of Lgr5+ Intestinal Stem Cells Both in Organoids and In Vivo. Cells, 2020, 9, 90.	4.1	3
47	Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. Pancreatology, 2020, 20, 101-109.	1.1	17
48	Stabilization of ERK-Phosphorylated METTL3 by USP5 Increases m6A Methylation. Molecular Cell, 2020, 80, 633-647.e7.	9.7	83
49	Cancer Cell Metabolism Bolsters Immunotherapy Resistance by Promoting an Immunosuppressive Tumor Microenvironment. Frontiers in Oncology, 2020, 10, 1197.	2.8	30
50	The lncRNA H19 alleviates muscular dystrophy by stabilizing dystrophin. Nature Cell Biology, 2020, 22, 1332-1345.	10.3	51
51	PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis. Nature Cell Biology, 2020, 22, 1264-1275.	10.3	508
52	Pharmacologic Suppression of B7-H4 Glycosylation Restores Antitumor Immunity in Immune-Cold Breast Cancers. Cancer Discovery, 2020, 10, 1872-1893.	9.4	66
53	Targeting positive feedback between BASP1 and EGFR as a therapeutic strategy for lung cancer progression. Theranostics, 2020, 10, 10925-10939.	10.0	20
54	Hepatoma cell-intrinsic TLR9 activation induces immune escape through PD-L1 upregulation in hepatocellular carcinoma. Theranostics, 2020, 10, 6530-6543.	10.0	31

#	Article	IF	Citations
55	Blocking immunosuppressive neutrophils deters pY696-EZH2â€“driven brain metastases. Science Translational Medicine, 2020, 12, .	12.4	64
56	Isolation of cancer-derived extracellular vesicle subpopulations by a size-selective microfluidic platform. Biomicrofluidics, 2020, 14, 034113.	2.4	29
57	ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis. Cancer Cell, 2020, 37, 324-339.e8.	16.8	126
58	The impact of PD-L1â€‰N-linked glycosylation on cancer therapy and clinical diagnosis. Journal of Biomedical Science, 2020, 27, 77.	7.0	89
59	Nuclear receptor tyrosine kinase transport and functions in cancer. Advances in Cancer Research, 2020, 147, 59-107.	5.0	16
60	Digital Receptor Occupancy Assay in Quantifying On- and Off-Target Binding Affinities of Therapeutic Antibodies. ACS Sensors, 2020, 5, 296-302.	7.8	2
61	The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2 for lipogenesis. Nature, 2020, 580, 530-535.	27.8	171
62	SLFN11 inhibits hepatocellular carcinoma tumorigenesis and metastasis by targeting RPS4X via mTOR pathway. Theranostics, 2020, 10, 4627-4643.	10.0	61
63	Targeting Glycosylated PD-1 Induces Potent Antitumor Immunity. Cancer Research, 2020, 80, 2298-2310.	0.9	87
64	Abstract 5682: Synergism of PARP inhibitor and MET inhibitor in multiple cancer types with intrinsic and acquired PARP inhibitor resistances. , 2020, , .		0
65	Abstract 6527: Targeting glycosylated PD-1 induces potent anti-tumor immunity. , 2020, , .		0
66	Abstract 5180: Nuclear receptor tyrosine kinase c-MET restrains efficacy of PARP inhibitor in pancreatic cancer cells. , 2020, , .		0
67	Abstract 4074: Reversing acquired PARPi resistance of TNBC through combined inhibition of cMet and EGFR. , 2020, , .		0
68	Abstract 1027: Inhibition of c-MET upregulates PD-L1 related immune escape in lung adenocarcinoma. , 2020, , .		1
69	Inhibition of c-MET upregulates PD-L1 expression in lung adenocarcinoma. American Journal of Cancer Research, 2020, 10, 564-571.	1.4	5
70	Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer. American Journal of Cancer Research, 2020, 10, 648-661.	1.4	15
71	Inhibition of CDK2 reduces EZH2 phosphorylation and reactivates ERÎ± expression in high-grade serous ovarian carcinoma. American Journal of Cancer Research, 2020, 10, 1194-1206.	1.4	4
72	The stabilization of PD-L1 by the endoplasmic reticulum stress protein GRP78 in triple-negative breast cancer. American Journal of Cancer Research, 2020, 10, 2621-2634.	1.4	8

#	Article	IF	Citations
73	High RPS3A expression correlates with low tumor immune cell infiltration and unfavorable prognosis in hepatocellular carcinoma patients. American Journal of Cancer Research, 2020, 10, 2768-2784.	1.4	6
74	Dasatinib Increases MHCII Surface Levels and Can Synergize with Anti-PD1 Therapy to Increase the Anti-Tumor Effect in a Pre-Clinical Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Model. Blood, 2020, 136, 44-44.	1.4	0
75	BIK ubiquitination by the E3 ligase Cul5-ASB11 determines cell fate during cellular stress. Journal of Cell Biology, 2019, 218, 3002-3018.	5.2	13
76	Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy. Cancer Cell, 2019, 36, 168-178.e4.	16.8	240
77	Mechanisms Controlling PD-L1 Expression in Cancer. Molecular Cell, 2019, 76, 359-370.	9.7	501
78	CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer. Nature Communications, 2019, 10, 5114.	12.8	64
79	ASPH-notch Axis guided Exosomal delivery of Prometastatic Secretome renders breast Cancer multi-organ metastasis. Molecular Cancer, 2019, 18, 156.	19.2	55
80	Tankyrase disrupts metabolic homeostasis and promotes tumorigenesis by inhibiting LKB1-AMPK signalling. Nature Communications, 2019, 10, 4363.	12.8	61
81	Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. Nature Immunology, 2019, 20, 835-851.	14.5	277
82	Activation of Aurora A kinase increases YAP stability via blockage of autophagy. Cell Death and Disease, 2019, 10, 432.	6.3	47
83	Racial profiling harms science. Science, 2019, 363, 1290-1292.	12.6	4
84	Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. Gut, 2019, 68, 1653-1666.	12.1	246
85	Functional roles of the human ribonuclease A superfamily in RNA metabolism and membrane receptor biology. Molecular Aspects of Medicine, 2019, 70, 106-116.	6.4	20
86	Assessing metastatic potential of breast cancer cells based on EGFR dynamics. Scientific Reports, 2019, 9, 3395.	3.3	45
87	H2O2 induces nuclear transport of the receptor tyrosine kinase c-MET in breast cancer cells via a membrane-bound retrograde trafficking mechanism. Journal of Biological Chemistry, 2019, 294, 8516-8528.	3.4	20
88	MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1. Gastroenterology, 2019, 156, 1849-1861.e13.	1.3	131
89	PTEN self-regulates through USP11 via the PI3K-FOXO pathway to stabilize tumor suppression. Nature Communications, 2019, 10, 636.	12.8	53
90	Expression and Clinical Significance of Protein Kinase RNAâ€“Like Endoplasmic Reticulum Kinase and Phosphorylated Eukaryotic Initiation Factor 2Î± in Pancreatic Ductal Adenocarcinoma. Pancreas, 2019, 48, 323-328.	1.1	10

#	Article	IF	Citations
91	Selective small molecule PARG inhibitor causes replication fork stalling and cancer cell death. Nature Communications, 2019, 10, 5654.	12.8	75
92	EGFR and c-MET Cooperate to Enhance Resistance to PARP Inhibitors in Hepatocellular Carcinoma. Cancer Research, 2019, 79, 819-829.	0.9	52
93	LncRNAs-directed PTEN enzymatic switch governs epithelialâ€“mesenchymal transition. Cell Research, 2019, 29, 286-304.	12.0	43
94	Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications. Journal of the National Cancer Institute, 2019, 111, 584-596.	6.3	125
95	Palmitoylation stabilizes PD-L1 to promote breast tumor growth. Cell Research, 2019, 29, 83-86.	12.0	158
96	PTEN-induced partial epithelial-mesenchymal transition drives diabetic kidney disease. Journal of Clinical Investigation, 2019, 129, 1129-1151.	8.2	68
97	IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. Journal of Clinical Investigation, 2019, 129, 3324-3338.	8.2	209
98	Abstract 845: c-MET nuclear transportation via membrane-bounded retrograde trafficking in breast cancer cells. , 2019, , .		0
99	Abstract LB-092: TKI insensitive role of EGFRconfers TKI resistance via PKCÎ´. , 2019, , .		0
100	Abstract LB-258: EGFR and c-MET cooperate to enhance PARP inhibitor resistance in hepatocellular carcinoma. , 2019, , .		0
101	Abstract B090: Tyrosine 211 phosphorylation of PCNA: A new paradigm of linking cell proliferation to cancer stemness and metastasis. , 2019, , .		0
102	An essential role of PRMT1-mediated EGFR methylation in EGFR activation by ribonuclease 5. American Journal of Cancer Research, 2019, 9, 180-185.	1.4	4
103	Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells. American Journal of Cancer Research, 2019, 9, 608-618.	1.4	12
104	The potential role of YAP in Axl-mediated resistance to EGFR tyrosine kinase inhibitors. American Journal of Cancer Research, 2019, 9, 2719-2729.	1.4	6
105	Abstract 4122: The regulatory mechanism of PD-L1 level through ER-associated degradation. , 2019, , .		0
106	Actin cytoskeleton remodeling drives epithelialâ€mesenchymal transition for hepatoma invasion and metastasis in mice. Hepatology, 2018, 67, 2226-2243.	7.3	108
107	Establishment of a human embryonic stem cell line with homozygous TP53 R248W mutant by TALEN mediated gene editing. Stem Cell Research, 2018, 29, 215-219.	0.7	9
108	ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer. Cell Reports, 2018, 23, 823-837.	6.4	42

#	Article	IF	Citations
109	Mechanisms of Action and Resistance of Trastuzumab in Breast Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2018, , 51-66.	0.1	0
110	Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function. Molecular Cell, 2018, 69, 279-291.e5.	9.7	138
111	Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1. Cancer Cell, 2018, 33, 187-201.e10.	16.8	381
112	A homozygous p53 R282W mutant human embryonic stem cell line generated using TALEN-mediated precise gene editing. Stem Cell Research, 2018, 27, 131-135.	0.7	9
113	Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. Cancer Cell, 2018, 33, 752-769.e8.	16.8	58
114	The role of PRMT1 in EGFR methylation and signaling in MDA-MB-468 triple-negative breast cancer cells. Breast Cancer, 2018, 25, 74-80.	2.9	40
115	EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer. Oncogene, 2018, 37, 208-217.	5.9	79
116	Effect of Epithelial-Mesenchymal Transition on EGFR Dynamics Revealed by Single-Particle Tracking. Biophysical Journal, 2018, 114, 534a.	0.5	0
117	Posttranslational Modifications of PD-L1 and Their Applications in Cancer Therapy. Cancer Research, 2018, 78, 6349-6353.	0.9	183
118	A novel ligand-receptor relationship between families of ribonucleases and receptor tyrosine kinases. Journal of Biomedical Science, 2018, 25, 83.	7.0	9
119	Targeting PKCÎ´ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer. Cancer Cell, 2018, 34, 954-969.e4.	16.8	56
120	Generation of an induced pluripotent stem cell line from an individual with a heterozygous RECQL4 mutation. Stem Cell Research, 2018, 33, 36-40.	0.7	3
121	Linear ubiquitination of cFLIP induced by LUBAC contributes to TNFÎ±-induced apoptosis. Journal of Biological Chemistry, 2018, 293, 20062-20072.	3.4	38
122	Suppression of stromal-derived Dickkopf-3 (DKK3) inhibits tumor progression and prolongs survival in pancreatic ductal adenocarcinoma. Science Translational Medicine, 2018, 10, .	12.4	33
123	Long noncoding RNA MALAT1 suppresses breast cancer metastasis. Nature Genetics, 2018, 50, 1705-1715.	21.4	561
124	The Adaptor Protein CARD9 Protects against Colon Cancer by Restricting Mycobiota-Mediated Expansion of Myeloid-Derived Suppressor Cells. Immunity, 2018, 49, 504-514.e4.	14.3	125
125	BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nature Cell Biology, 2018, 20, 1181-1192.	10.3	565
126	STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Nature Communications, 2018, 9, 1908.	12.8	282

#	Article	IF	Citations
127	Juxtacrine Signaling Inhibits Antitumor Immunity by Upregulating PD-L1 Expression. Cancer Research, 2018, 78, 3761-3768.	0.9	22
128	Expression of Long Noncoding RNA YIYA Promotes Glycolysis in Breast Cancer. Cancer Research, 2018, 78, 4524-4532.	0.9	59
129	Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth. Cell Research, 2018, 28, 862-864.	12.0	345
130	Activation of phagocytosis by immune checkpoint blockade. Frontiers of Medicine, 2018, 12, 473-480.	3.4	15
131	Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2018, 24, 5744-5756.	7.0	35
132	Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1. Molecular Cell, 2018, 71, 606-620.e7.	9.7	491
133	A flow-proteometric platform for analyzing protein concentration (FAP): Proof of concept for quantification of PD-L1 protein in cells and tissues. Biosensors and Bioelectronics, 2018, 117, 97-103.	10.1	6
134	CDK4/6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: Are we at the finish line?. Oncotarget, 2018, 9, 34193-34195.	1.8	2
135	Abstract 5606: Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1. , 2018, , .		0
136	Abstract 3205: Histone tyrosine phosphorylation determines glioblastoma cell survival. , 2018, , .		0
137	Single oral dose acute and subacute toxicity of a c-MET tyrosine kinase inhibitor and CDK 4/6 inhibitor combination drug therapy. American Journal of Cancer Research, 2018, 8, 183-191.	1.4	2
138	YY1 and HDAC9c transcriptionally regulate p38-mediated mesenchymal stem cell differentiation into osteoblasts. American Journal of Cancer Research, 2018, 8, 514-525.	1.4	7
139	Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing. American Journal of Cancer Research, 2018, 8, 1307-1316.	1.4	42
140	Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer. American Journal of Cancer Research, 2018, 8, 1837-1846.	1.4	26
141	A ROR1â€“HER3â€“lncRNA signalling axis modulates the Hippoâ€“YAP pathway to regulate bone metastasis. Nature Cell Biology, 2017, 19, 106-119.	10.3	253
142	JNK1 negatively controls antifungal innate immunity by suppressing CD23 expression. Nature Medicine, 2017, 23, 337-346.	30.7	89
143	A UBE2O-AMPKÎ±2 Axis that Promotes Tumor Initiation and Progression Offers Opportunities for Therapy. Cancer Cell, 2017, 31, 208-224.	16.8	98
144	The LINK-A lncRNA interacts with PtdIns(3,4,5)P3 toÂhyperactivate AKTÂand confer resistance to AKTÂinhibitors. Nature Cell Biology, 2017, 19, 238-251.	10.3	201

#	Article	IF	Citations
145	Induction of NKG2D Ligands on Solid Tumors Requires Tumor-Specific CD8+ T Cells and Histone Acetyltransferases. Cancer Immunology Research, 2017, 5, 300-311.	3.4	20
146	Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma. Nature Communications, 2017, 8, 14437.	12.8	77
147	Lymphotoxin-Î² Interacts with Methylated EGFR to Mediate Acquired Resistance to Cetuximab in Head and Neck Cancer. Clinical Cancer Research, 2017, 23, 4388-4401.	7.0	24
148	POMC maintains tumor-initiating properties of tumor tissue-derived long-term-cultured breast cancer stem cells. International Journal of Cancer, 2017, 140, 2517-2525.	5.1	10
149	PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. Clinical Cancer Research, 2017, 23, 3711-3720.	7.0	710
150	Argininosuccinate synthetase 1 (ASS1) is a common metabolic marker of chemosensitivity for targeted arginine- and glutamine-starvation therapy. Cancer Letters, 2017, 388, 54-63.	7.2	32
151	PARP inhibitors as precision medicine for cancer treatment. National Science Review, 2017, 4, 576-592.	9.5	12
152	A hypoxia-responsive TRAF6â€“ATMâ€“H2AX signalling axis promotes HIF1Î± activation, tumorigenesis andÂmetastasis. Nature Cell Biology, 2017, 19, 38-51.	10.3	83
153	The role of T-cell immunoglobulin mucin-3 and its ligand galectin-9 in antitumor immunity and cancer immunotherapy. Science China Life Sciences, 2017, 60, 1058-1064.	4.9	19
154	Structural and Functional Impacts of ER Coactivator Sequential Recruitment. Molecular Cell, 2017, 67, 733-743.e4.	9.7	69
155	TIE2 Associates with Caveolae and Regulates Caveolin-1 To Promote Their Nuclear Translocation. Molecular and Cellular Biology, 2017, 37, .	2.3	15
156	Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with Î²-blockers. Science Translational Medicine, 2017, 9, .	12.4	96
157	Pneumatically Actuated Soft Micromold Device for Fabricating Collagen and Matrigel Microparticles. Soft Robotics, 2017, 4, 390-399.	8.0	6
158	Aurora A kinase activates YAP signaling in triple-negative breast cancer. Oncogene, 2017, 36, 1265-1275.	5.9	47
159	Nanoparticle Delivery of miR-34a Eradicates Long-term-cultured Breast Cancer Stem Cells via Targeting C22ORF28 Directly. Theranostics, 2017, 7, 4805-4824.	10.0	51
160	Intracaecal Orthotopic Colorectal Cancer Xenograft Mouse Model. Bio-protocol, 2017, 7, .	0.4	12
161	Metastasis regulation by PPARD expression in cancer cells. JCI Insight, 2017, 2, e91419.	5.0	58
162	HIF-1Î± promotes autophagic proteolysis of Dicer and enhances tumor metastasis. Journal of Clinical Investigation, 2017, 128, 625-643.	8.2	56

#	Article	IF	Citations
163	JAK2-binding long noncoding RNA promotes breast cancer brain metastasis. Journal of Clinical Investigation, 2017, 127, 4498-4515.	8.2	177
164	Rational combination of immunotherapy for triple negative breast cancer treatment. Chinese Clinical Oncology, 2017, 6, 54-54.	1.2	10
165	Abstract B47: Stabilization of programmed death ligand-1 by epidermal growth factor enhances cancer cell immune escape. , 2017, , .		0
166	Arginine methylation of EGFR in circulating tumor cells: A new biomarker for predicting resistance to anti-EGFR agents.. Journal of Clinical Oncology, 2017, 35, 3590-3590.	1.6	0
167	Abstract LB-131: Targeting expression of EZH2 with increased H3K27 trimethylation activity drives and synergizes with oncogene to promote mammary tumorigenesis in genetically engineered mouse models. , 2017, , .		0
168	Abstract 3: Targeting epigenetic modifiers in diffuse large B-cell lymphoma. , 2017, , .		0
169	Abstract 5854: TIE2-mediated epigenetic marks regulate therapeutic resistance of glioblastoma. , 2017, , .		0
170	Abstract 4713: Deubiquitination and stabilization of programmed cell death-ligand 1 by CSN5. , 2017, , .		0
171	Abstract 3028: Reactive oxygen species induced nuclear translocation of c-MET via INTERNET mechanism. , 2017, , .		0
172	A tumor vessel-targeting fusion protein elicits a chemotherapeutic bystander effect in pancreatic ductal adenocarcinoma. American Journal of Cancer Research, 2017, 7, 657-672.	1.4	3
173	Arginine methylation of EGFR: a new biomarker for predicting resistance to anti-EGFR treatment. American Journal of Cancer Research, 2017, 7, 2587-2599.	1.4	2
174	Upregulation of lactate dehydrogenase a by 14-3-3Î¶ leads to increased glycolysis critical for breast cancer initiation and progression. Oncotarget, 2016, 7, 35270-35283.	1.8	27
175	Enhancer of Zeste Homolog 2 and Histone Deacetylase 9c Regulate Age-Dependent Mesenchymal Stem Cell Differentiation into Osteoblasts and Adipocytes. Stem Cells, 2016, 34, 2183-2193.	3.2	43
176	The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. Cancer and Metastasis Reviews, 2016, 35, 575-588.	5.9	237
177	Linking genomic reorganization to tumor initiation via the giant cell cycle. Oncogenesis, 2016, 5, e281-e281.	4.9	121
178	Dicer Elicits Paclitaxel Chemosensitization and Suppresses Cancer Stemness in Breast Cancer by Repressing AXL. Cancer Research, 2016, 76, 3916-3928.	0.9	17
179	Altered Expression and Splicing of ESRP1 in Malignant Melanoma Correlates with Epithelialâ€“Mesenchymal Status and Tumor-Associated Immune Cytolytic Activity. Cancer Immunology Research, 2016, 4, 552-561.	3.4	50
180	Powering Tumor Metastasis with Recycled Fuel. Cancer Cell, 2016, 30, 374-375.	16.8	4

#	Article	IF	Citations
181	Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nature Communications, 2016, 7, 12632.	12.8	648
182	ERK Activation Globally Downregulates miRNAs through Phosphorylating Exportin-5. Cancer Cell, 2016, 30, 723-736.	16.8	125
183	Segmentation of 3D Trajectories Acquired by TSUNAMI Microscope: An Application to EGFR Trafficking. Biophysical Journal, 2016, 111, 2214-2227.	0.5	28
184	Deubiquitination and Stabilization of PD-L1 by CSN5. Cancer Cell, 2016, 30, 925-939.	16.8	538
185	Oncogenic Functions of Gli1 in Pancreatic Adenocarcinoma Are Supported by Its PRMT1-Mediated Methylation. Cancer Research, 2016, 76, 7049-7058.	0.9	51
186	TIE2-mediated tyrosine phosphorylation of H4 regulates DNA damage response by recruiting ABL1. Science Advances, 2016, 2, e1501290.	10.3	33
187	Inhibition of VEGF165/VEGFR2-dependent signaling by LECT2 suppresses hepatocellular carcinoma angiogenesis. Scientific Reports, 2016, 6, 31398.	3.3	22
188	Suspension survival mediated by PP2A-STAT3-Col XVII determines tumour initiation and metastasis in cancer stem cells. Nature Communications, 2016, 7, 11798.	12.8	39
189	A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. Nature Communications, 2016, 7, 11169.	12.8	100
190	Development of automated high throughput single molecular microfluidic detection platform for signal transduction analysis. Proceedings of SPIE, 2016, , .	0.8	3
191	Dynamics of EGFR Trafficking from Membrane into Deep Cytoplasm Revealed by a Spatiotemporally Multiplexed 3D Tracking Microscope. Biophysical Journal, 2016, 110, 638a.	0.5	0
192	A Positive TGF-Î²/c-KIT Feedback Loop Drives Tumor Progression in Advanced Primary Liver Cancer. Neoplasia, 2016, 18, 371-386.	5.3	27
193	Analysis of Individual Signaling Complexes by mMAPS, a Flowâ€Proteometric System. Current Protocols in Molecular Biology, 2016, 114, 20.11.1-20.11.22.	2.9	3
194	Nuclear AURKA acquires kinase-independent transactivating function to enhance breast cancer stem cell phenotype. Nature Communications, 2016, 7, 10180.	12.8	142
195	AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation. Cancer Research, 2016, 76, 1451-1462.	0.9	65
196	EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape. Cancer Research, 2016, 76, 1284-1296.	0.9	190
197	Blocking c-Metâ€“mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nature Medicine, 2016, 22, 194-201.	30.7	189
198	Severe Hepatitis Promotes Hepatocellular Carcinoma Recurrence via NF-ÎºB Pathway-Mediated Epithelialâ€“Mesenchymal Transition after Resection. Clinical Cancer Research, 2016, 22, 1800-1812.	7.0	25

#	Article	IF	Citations
199	The LINK-A lncRNA activates normoxic HIF1Î± signalling in triple-negative breast cancer. Nature Cell Biology, 2016, 18, 213-224.	10.3	444
200	JARID1D Is a Suppressor and Prognostic Marker of Prostate Cancer Invasion and Metastasis. Cancer Research, 2016, 76, 831-843.	0.9	99
201	Deacetylation of HSPA5 by HDAC6 leads to GP78-mediated HSPA5 ubiquitination at K447 and suppresses metastasis of breast cancer. Oncogene, 2016, 35, 1517-1528.	5.9	61
202	High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma. Oncogene, 2016, 35, 1565-1574.	5.9	72
203	Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer. Oncogene, 2016, 35, 2186-2196.	5.9	26
204	GSK3Î² inactivation promotes the oncogenic functions of EZH2 and enhances methylation of H3K27 in human breast cancers. Oncotarget, 2016, 7, 57131-57144.	1.8	35
205	MZF-1/Elk-1 interaction domain as therapeutic target for protein kinase CÎ±-based triple-negative breast cancer cells. Oncotarget, 2016, 7, 59845-59859.	1.8	18
206	Sciellin mediates mesenchymal-to-epithelial transition in colorectal cancer hepatic metastasis. Oncotarget, 2016, 7, 25742-25754.	1.8	20
207	Nanofluidic Strategies for Cancer Research. RSC Nanoscience and Nanotechnology, 2016, , 114-149.	0.2	0
208	Abstract LB-119: Single-cell live imaging of paclitaxel-resistant cancer cell generation. , 2016, , .		0
209	Abstract LB-002: Methylation of the EGF receptor regulates signaling and therapeutic response. , 2016, , .		0
210	Extracellular PKM2 induces cancer proliferation by activating the EGFR signaling pathway. American Journal of Cancer Research, 2016, 6, 628-38.	1.4	21
211	Regulation of therapeutic resistance in cancers by receptor tyrosine kinases. American Journal of Cancer Research, 2016, 6, 827-42.	1.4	9
212	A perspective on anti-EGFR therapies targeting triple-negative breast cancer. American Journal of Cancer Research, 2016, 6, 1609-23.	1.4	121
213	Proteolytic cleavage, trafficking, and functions of nuclear receptor tyrosine kinases. FEBS Journal, 2015, 282, 3693-3721.	4.7	73
214	E1A-Mediated Inhibition of HSPA5 Suppresses Cell Migration and Invasion in Triple-Negative Breast Cancer. Annals of Surgical Oncology, 2015, 22, 889-898.	1.5	20
215	14-3-3Î¶ Turns TGF-Î²â€™s Function from Tumor Suppressor to Metastasis Promoter in Breast Cancer by Contextual Changes of Smad Partners from p53 to Gli2. Cancer Cell, 2015, 27, 177-192.	16.8	158
216	Signaling-Mediated Regulation of MicroRNA Processing. Cancer Research, 2015, 75, 783-791.	0.9	46

#	Article	IF	Citations
217	Tyrosine 370 phosphorylation of ATM positively regulates DNA damage response. Cell Research, 2015, 25, 225-236.	12.0	54
218	HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer. Molecular Oncology, 2015, 9, 586-600.	4.6	31
219	Novel therapeutic strategy targeting the Hedgehog signalling and mTOR pathways in biliary tract cancer. British Journal of Cancer, 2015, 112, 1042-1051.	6.4	36
220	The ZNF304-integrin axis protects against anoikis in cancer. Nature Communications, 2015, 6, 7351.	12.8	48
221	Aberrant Expression of proPTPRN2 in Cancer Cells Confers Resistance to Apoptosis. Cancer Research, 2015, 75, 1846-1858.	0.9	24
222	The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer. Clinical Cancer Research, 2015, 21, 2580-2590.	7.0	199
223	Modeling Familial Cancer with Induced Pluripotent Stem Cells. Cell, 2015, 161, 240-254.	28.9	191
224	Erythropoietin Stimulates Tumor Growth via EphB4. Cancer Cell, 2015, 28, 610-622.	16.8	94
225	Deep and high-resolution three-dimensional tracking of single particles using nonlinear and multiplexed illumination. Nature Communications, 2015, 6, 7874.	12.8	81
226	Interplay between arginine methylation and ubiquitylation regulates KLF4-mediated genome stability and carcinogenesis. Nature Communications, 2015, 6, 8419.	12.8	107
227	The effect of ephrin-A1 on resistance to Photofrin-mediated photodynamic therapy in esophageal squamous cell carcinoma cells. Lasers in Medical Science, 2015, 30, 2353-2361.	2.1	11
228	FOXC1 Activates Smoothened-Independent Hedgehog Signaling in Basal-like Breast Cancer. Cell Reports, 2015, 13, 1046-1058.	6.4	124
229	Biochemical Fractionation of Membrane Receptors in the Nucleus. Methods in Molecular Biology, 2015, 1234, 99-112.	0.9	2
230	Nuclear Functions of Receptor Tyrosine Kinases. , 2015, , 77-109.		1
231	Abstract LB-202: 14-3-3Î¶ turns TGF-Î²'s function from tumor suppressor to metastasis promoter in breast cancer by contextual changes of Smad partners from p53 to Gli2. , 2015, , .		1
232	PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response. Journal of Clinical Investigation, 2015, 125, 4529-4543.	8.2	114
233	Targeted expression of BikDD combined with metronomic doxorubicin induces synergistic antitumor effect through Bax activation in hepatocellular carcinoma. Oncotarget, 2015, 6, 23807-23819.	1.8	5
234	miRNA-7/21/107 contribute to HBx-induced hepatocellular carcinoma progression through suppression of maspin. Oncotarget, 2015, 6, 25962-25974.	1.8	29

#	Article	IF	Citations
235	Abstract B03: Cisplatin-resistant cells possess collateral sensitivity to folate antimetabolites. , 2015, , .		0
236	Abstract 5129: Model osteosarcoma by Li-Fraumeni syndrome patient-specific induced pluripotent stem cells. , 2015, , .		0
237	Abstract 5120: Using flow-proteometric platform to analyze individual signaling complexes in tumor tissue. , 2015, , .		0
238	Abstract 3298: ABL1 is required for Tie2-mediated DNA repair in brain tumor stem cells. , 2015, , .		0
239	Abstract 2895: Phosphorylation of EZH2 at T416 by CDK2 promotes development of mammary tumors with basal-like phenotype. , 2015, , .		0
240	Abstract 3900: Genomic landscape of human cancer reveals dysregulated TGF-Î² signaling with prognostic significance. , 2015, , .		0
241	Abstract 1962: TGF-Î²/SMAD2 signaling drives tumor-progression via c-KIT/STAT3-signaling in advanced HCC. , 2015, , .		0
242	Abstract 3911: A positive feedback loop between TGF-Î² and SCF mediates TGF-Î²1 ligand overexpression in advanced hepatocellular carcinoma. , 2015, , .		0
243	Proteasome inhibition enhances the killing effect of BikDD gene therapy. American Journal of Translational Research (discontinued), 2015, 7, 319-27.	0.0	5
244	Phosphorylation of EZH2 at T416 by CDK2 contributes to the malignancy of triple negative breast cancers. American Journal of Translational Research (discontinued), 2015, 7, 1009-20.	0.0	28
245	Non-canonical signaling mode of the epidermal growth factor receptor family. American Journal of Cancer Research, 2015, 5, 2944-58.	1.4	25
246	Safety and efficacy of quadrapeutics versus chemoradiation in head and neck carcinoma xenograft model. American Journal of Cancer Research, 2015, 5, 3534-47.	1.4	0
247	Carglumic acid promotes apoptosis and suppresses cancer cell proliferation in vitro and in vivo. American Journal of Cancer Research, 2015, 5, 3560-9.	1.4	8
248	Selective expression of constitutively active pro-apoptotic protein BikDD gene in primary mammary tumors inhibits tumor growth and reduces tumor initiating cells. American Journal of Cancer Research, 2015, 5, 3624-34.	1.4	1
249	Regulation and Role of EZH2 in Cancer. Cancer Research and Treatment, 2014, 46, 209-222.	3.0	243
250	ADAM9 Promotes Lung Cancer Metastases to Brain by a Plasminogen Activator-Based Pathway. Cancer Research, 2014, 74, 5229-5243.	0.9	70
251	Expression of metastasis suppressor BRMS1 in breast cancer cells results in a marked delay in cellular adhesion to matrix. Molecular Carcinogenesis, 2014, 53, 1011-1026.	2.7	17
252	miR-100 Induces Epithelial-Mesenchymal Transition but Suppresses Tumorigenesis, Migration and Invasion. PLoS Genetics, 2014, 10, e1004177.	3.5	110

#	Article	IF	Citations
253	mMAPS: A Flow-Proteometric Technique to Analyze Protein-Protein Interactions in Individual Signaling Complexes. Science Signaling, 2014, 7, rs1.	3.6	7
254	Targeted BikDD Expression Kills Androgen-Dependent and Castration-Resistant Prostate Cancer Cells. Molecular Cancer Therapeutics, 2014, 13, 1813-1825.	4.1	13
255	miR326 Maturation Is Crucial for VEGF-Câ€“Driven Cortactin Expression and Esophageal Cancer Progression. Cancer Research, 2014, 74, 6280-6290.	0.9	31
256	Sustained activation of SMAD3/SMAD4 by FOXM1 promotes TGF-Î²â€“dependent cancer metastasis. Journal of Clinical Investigation, 2014, 124, 564-579.	8.2	155
257	MDM2-mediated degradation of SIRT6 phosphorylated by AKT1 promotes tumorigenesis and trastuzumab resistance in breast cancer. Science Signaling, 2014, 7, ra71.	3.6	90
258	Receptor Tyrosine Kinases in the Nucleus: Nuclear Functions and Therapeutic Implications in Cancers. Cancer Drug Discovery and Development, 2014, , 189-229.	0.4	5
259	Efficient systemic DNA delivery to the tumor by self-assembled nanoparticle. Journal of Nanoparticle Research, 2014, 16, 1.	1.9	2
260	The Anti-Tumor Activity of E1A and its Implications in Cancer Therapy. Archivum Immunologiae Et Therapiae Experimentalis, 2014, 62, 195-204.	2.3	14
261	Block-Cell-Printing for live single-cell printing. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 2948-2953.	7.1	122
262	lncRNA Directs Cooperative Epigenetic Regulation Downstream of Chemokine Signals. Cell, 2014, 159, 1110-1125.	28.9	393
263	ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1. Nature Cell Biology, 2014, 16, 864-875.	10.3	367
264	EGFR Modulates DNA Synthesis and Repair through Tyr Phosphorylation of Histone H4. Developmental Cell, 2014, 30, 224-237.	7.0	67
265	EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer. Journal of Experimental and Clinical Cancer Research, 2014, 33, 58.	8.6	23
266	Definition of PKC-Î±, CDK6, and MET as Therapeutic Targets in Triple-Negative Breast Cancer. Cancer Research, 2014, 74, 4822-4835.	0.9	61
267	IKKÎ± restoration via EZH2 suppression induces nasopharyngeal carcinoma differentiation. Nature Communications, 2014, 5, 3661.	12.8	67
268	Hippo Coactivator YAP1 Upregulates SOX9 and Endows Esophageal Cancer Cells with Stem-like Properties. Cancer Research, 2014, 74, 4170-4182.	0.9	219
269	Gain-of-Function Mutant p53 Promotes Cell Growth and Cancer Cell Metabolism via Inhibition of AMPK Activation. Molecular Cell, 2014, 54, 960-974.	9.7	196
270	Syntaxin 6-mediated Golgi translocation plays an important role in nuclear functions of EGFR through microtubule-dependent trafficking. Oncogene, 2014, 33, 756-770.	5.9	51

#	Article	IF	Citations
271	Signaling cross-talk in the resistance to HER family receptor targeted therapy. Oncogene, 2014, 33, 1073-1081.	5.9	99
272	MicroRNA-205 signaling regulates mammary stem cell fate and tumorigenesis. Journal of Clinical Investigation, 2014, 124, 3093-3106.	8.2	99
273	De-acetylation and degradation of HSPA5 is critical for E1A metastasis suppression in breast cancer cells. Oncotarget, 2014, 5, 10558-10570.	1.8	27
274	Abstract 2784: Targeting TGF-Î² regulated E3 ligases: a novel therapeutic approach for primary liver cancer. , 2014, , .		0
275	Abstract 5146: The histone demethylase KDM2A is a new promoter of tumorigenesis, drug target and negative prognostic biomarker for non-small cell lung cancer. , 2014, , .		1
276	Abstract 3896: The Hippo coactivator YAP1 upregulates SOX9 and endows cancer stem cell properties in non-transformed cells and esophageal cancer cells. , 2014, , .		0
277	Abstract A49: S6K1 promotes invasiveness of breast cancer cells in a novel model of triple-negative breast cancer metastasis. , 2014, , .		4
278	S6K1 promotes invasiveness of breast cancer cells in a model of metastasis of triple-negative breast cancer. American Journal of Translational Research (discontinued), 2014, 6, 361-76.	0.0	32
279	Activation of Keap1/Nrf2 signaling pathway by nuclear epidermal growth factor receptor in cancer cells. American Journal of Translational Research (discontinued), 2014, 6, 649-63.	0.0	16
280	Pharmacological Inactivation of Skp2 SCF Ubiquitin Ligase Restricts Cancer Stem Cell Traits and Cancer Progression. Cell, 2013, 154, 556-568.	28.9	335
281	TIG1 Promotes the Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase. Cancer Research, 2013, 73, 6516-6525.	0.9	70
282	Deubiquitylation and stabilization of PTEN by USP13. Nature Cell Biology, 2013, 15, 1486-1494.	10.3	172
283	MiR-520h-mediated FOXC2 regulation is critical for inhibition of lung cancer progression by resveratrol. Oncogene, 2013, 32, 431-443.	5.9	116
284	Epigenetic Regulation of the miR142-3p/Interleukin-6 Circuit in Glioblastoma. Molecular Cell, 2013, 52, 693-706.	9.7	83
285	A Tumorigenic Factor Interactome Connected through Tumor Suppressor MicroRNA-198 in Human Pancreatic Cancer. Clinical Cancer Research, 2013, 19, 5901-5913.	7.0	70
286	RASAL2: Wrestling in the Combat of Ras Activation. Cancer Cell, 2013, 24, 277-279.	16.8	8
287	The effects of Photofrin-mediated photodynamic therapy on the modulation of EGFR in esophageal squamous cell carcinoma cells. Lasers in Medical Science, 2013, 28, 605-614.	2.1	20
288	Loss of FBP1 by Snail-Mediated Repression Provides Metabolic Advantages in Basal-like Breast Cancer. Cancer Cell, 2013, 23, 316-331.	16.8	660

#	Article	IF	Citations
289	EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2. Nature, 2013, 497, 383-387.	27.8	321
290	Epidermal Growth Factor Receptor Potentiates MCM7-Mediated DNA Replication through Tyrosine Phosphorylation of Lyn Kinase in Human Cancers. Cancer Cell, 2013, 23, 796-810.	16.8	54
291	EGFR-SGLT1 interaction does not respond to EGFR modulators, but inhibition of SGLT1 sensitizes prostate cancer cells to EGFR tyrosine kinase inhibitors. Prostate, 2013, 73, 1453-1461.	2.3	36
292	Mesenchymal stem cells promote growth and angiogenesis of tumors in mice. Oncogene, 2013, 32, 4343-4354.	5.9	187
293	Colon cancer stem cells resist antiangiogenesis therapy-induced apoptosis. Cancer Letters, 2013, 328, 226-234.	7.2	44
294	Beyond NF-Î¹B activation: nuclear functions of IÎ¹B kinase Î±. Journal of Biomedical Science, 2013, 20, 3.	7.0	90
295	Targeted endostatin-cytosine deaminase fusion gene therapy plus 5-fluorocytosine suppresses ovarian tumor growth. Oncogene, 2013, 32, 1082-1090.	5.9	20
296	SRC-3 coactivator regulates cell resistance to cytotoxic stress via TRAF4-mediated p53 destabilization. Genes and Development, 2013, 27, 274-287.	5.9	41
297	Caspase-Independent Cell Death Is Involved in the Negative Effect of EGF Receptor Inhibitors on Cisplatin in Nonâ€“Small Cell Lung Cancer Cells. Clinical Cancer Research, 2013, 19, 845-854.	7.0	93
298	Smurf2â€mediated degradation of EZH2 enhances neuron differentiation and improves functional recovery after ischaemic stroke. EMBO Molecular Medicine, 2013, 5, 531-547.	6.9	94
299	Lapatinib-Mediated Cyclooxygenase-2 Expression via Epidermal Growth Factor Receptor/HuR Interaction Enhances the Aggressiveness of Triple-Negative Breast Cancer Cells. Molecular Pharmacology, 2013, 83, 857-869.	2.3	31
300	Targeting the EGFR/PCNA Signaling Suppresses Tumor Growth of Triple-Negative Breast Cancer Cells with Cell-Penetrating PCNA Peptides. PLoS ONE, 2013, 8, e61362.	2.5	52
301	Inhibition of Type I Insulin-Like Growth Factor Receptor Signaling Attenuates the Development of Breast Cancer Brain Metastasis. PLoS ONE, 2013, 8, e73406.	2.5	31
302	Nuclear Functions and Trafficking of Receptor Tyrosine Kinases. , 2013, , 159-176.		3
303	Abstract 5169: Flow-proteometric analysis of single signaling complex.. , 2013, , .		14
304	KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling. Journal of Clinical Investigation, 2013, 123, 5231-5246.	8.2	164
305	In Vivo Targeting of ADAM9 Gene Expression Using Lentivirus-Delivered shRNA Suppresses Prostate Cancer Growth by Regulating REG4 Dependent Cell Cycle Progression. PLoS ONE, 2013, 8, e53795.	2.5	28
306	Abstract C171: Novel therapeutic strategies targeting the hedgehog signaling pathway and mTOR pathway in biliary tract cancer (BTC).. , 2013, , .		0

#	Article	IF	Citations
307	Beyond anti-VEGF: dual-targeting antiangiogenic and antiproliferative therapy. American Journal of Translational Research (discontinued), 2013, 5, 393-403.	0.0	21
308	Exogenous expression of human SGLT1 exhibits aggregations in sodium dodecyl sulfate polyacrylamide gel electrophoresis. American Journal of Translational Research (discontinued), 2013, 5, 441-9.	0.0	5
309	Targeted Expression of BikDD Eliminates Breast Cancer with Virtually No Toxicity in Noninvasive Imaging Models. Molecular Cancer Therapeutics, 2012, 11, 1915-1924.	4.1	23
310	On Mammary Gland Growth Factors: Roles in Normal Development and in Cancer. Cold Spring Harbor Perspectives in Biology, 2012, 4, a013532-a013532.	5.5	3
311	Microfluidic three-dimensional hydrodynamic flow focusing for the rapid protein concentration analysis. Biomicrofluidics, 2012, 6, 24132.	2.4	10
312	The role of EZH2 in tumour progression. British Journal of Cancer, 2012, 106, 243-247.	6.4	307
313	Nuclear EGFR Suppresses Ribonuclease Activity of Polynucleotide Phosphorylase through DNAPK-mediated Phosphorylation at Serine 776. Journal of Biological Chemistry, 2012, 287, 31015-31026.	3.4	43
314	Identification of a GÎ±GÎ²Î³, AKT and PKCÎ± signalome associated with invasive growth in two genetic models of human breast cancer cell epithelial-to-mesenchymal transition. International Journal of Oncology, 2012, 41, 189-200.	3.3	11
315	Epithelialâ€“Mesenchymal Transition Induced by TNF-Î± Requires NF-ÎºBâ€“Mediated Transcriptional Upregulation of Twist1. Cancer Research, 2012, 72, 1290-1300.	0.9	406
316	Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR. Oncogene, 2012, 31, 4372-4383.	5.9	47
317	Targeted Expression of miR-34a Using the T-VISA System Suppresses Breast Cancer Cell Growth and Invasion. Molecular Therapy, 2012, 20, 2326-2334.	8.2	85
318	Regulation of Embryonic and Induced Pluripotency by Aurora Kinase-p53 Signaling. Cell Stem Cell, 2012, 11, 179-194.	11.1	142
319	IKKÎ± Activation of NOTCH Links Tumorigenesis via FOXA2 Suppression. Molecular Cell, 2012, 45, 171-184.	9.7	83
320	The Skp2-SCF E3 Ligase Regulates Akt Ubiquitination, Glycolysis, Herceptin Sensitivity, and Tumorigenesis. Cell, 2012, 149, 1098-1111.	28.9	332
321	LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nature Medicine, 2012, 18, 1511-1517.	30.7	361
322	RAC1 activation mediates Twist1-induced cancer cell migration. Nature Cell Biology, 2012, 14, 366-374.	10.3	217
323	Dysregulation of MicroRNAs in cancer. Journal of Biomedical Science, 2012, 19, 90.	7.0	127
324	Nuclear functions and subcellular trafficking mechanisms of the epidermal growth factor receptor family. Cell and Bioscience, 2012, 2, 13.	4.8	128

#	Article	IF	Citations
325			

#	Article	IF	Citations
343	Abstract 3465: The effect of ephrin-A1 on the resistance of photodynamic therapy in esophageal cancer cells. , 2012, , .		0
344	Long non-coding RNAs: versatile master regulators of gene expression and crucial players in cancer. American Journal of Translational Research (discontinued), 2012, 4, 127-50.	0.0	141
345	EZH2: a pivotal regulator in controlling cell differentiation. American Journal of Translational Research (discontinued), 2012, 4, 364-75.	0.0	39
346	The Role of p27 Kip1 in Dasatinib-Enhanced Paclitaxel Cytotoxicity in Human Ovarian Cancer Cells. Journal of the National Cancer Institute, 2011, 103, 1403-1422.	6.3	26
347	Mesenchymal Stem Cells Promote Formation of Colorectal Tumors in Mice. Gastroenterology, 2011, 141, 1046-1056.	1.3	154
348	Astrocytes Upregulate Survival Genes in Tumor Cells and Induce Protection from Chemotherapy. Neoplasia, 2011, 13, 286-298.	5.3	224
349	Acetylation of EGF receptor contributes to tumor cell resistance to histone deacetylase inhibitors. Biochemical and Biophysical Research Communications, 2011, 404, 68-73.	2.1	39
350	Controlled Extracellular Matrix Degradation in Breast Cancer Tumors Improves Therapy by Trastuzumab. Molecular Therapy, 2011, 19, 479-489.	8.2	59
351	Elevated BCRP/ABCG2 Expression Confers Acquired Resistance to Gefitinib in Wild-Type EGFR-Expressing Cells. PLoS ONE, 2011, 6, e21428.	2.5	77
352	Deciphering the Role of Forkhead Transcription Factors in Cancer Therapy. Current Drug Targets, 2011, 12, 1284-1290.	2.1	70
353	CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells. Nature Cell Biology, 2011, 13, 87-94.	10.3	339
354	Crosstalk between ArgÂ1175 methylation and TyrÂ1173 phosphorylation negatively modulates EGFR-mediated ERK activation. Nature Cell Biology, 2011, 13, 174-181.	10.3	192
355	p53 regulates epithelialâ€“mesenchymal transition and stem cell properties through modulating miRNAs. Nature Cell Biology, 2011, 13, 317-323.	10.3	674
356	Vimentin is a novel AKT1 target mediating motility and invasion. Oncogene, 2011, 30, 457-470.	5.9	195
357	Targeted hepatocellular carcinoma proapoptotic BikDD gene therapy. Oncogene, 2011, 30, 1773-1783.	5.9	25
358	CHM-1 induces apoptosis via p38-mediated upregulation of DR5 expression in human ovarian cancer SKOV3 cells. European Journal of Pharmacology, 2011, 670, 96-104.	3.5	15
359	Implication of nuclear EGFR in the development of resistance to anticancer therapies. BioMedicine		

#	Article	IF	Citations
361	BikDD Eliminates Breast Cancer Initiating Cells and Synergizes with Lapatinib for Breast Cancer Treatment. Cancer Cell, 2011, 20, 341-356.	16.8	67
362	Tid1, CHIP and ErbB2 interactions and their prognostic implications for breast cancer patients. Journal of Pathology, 2011, 225, 424-437.	4.5	49
363	Targeting Tyrosine Phosphorylation of PCNA Inhibits Prostate Cancer Growth. Molecular Cancer Therapeutics, 2011, 10, 29-36.	4.1	73
364	Protein localization in disease and therapy. Journal of Cell Science, 2011, 124, 3381-3392.	2.0	346
365	Cytokine Receptor CXCR4 Mediates Estrogen-Independent Tumorigenesis, Metastasis, and Resistance to Endocrine Therapy in Human Breast Cancer. Cancer Research, 2011, 71, 603-613.	0.9	140
366	Nuclear ErbB2 Enhances Translation and Cell Growth by Activating Transcription of Ribosomal RNA Genes. Cancer Research, 2011, 71, 4269-4279.	0.9	63
367	FOXO3a-Dependent Mechanism of E1A-Induced Chemosensitization. Cancer Research, 2011, 71, 6878-6887.	0.9	42
368	Cancer-Targeted BikDD Gene Therapy Elicits Protective Antitumor Immunity against Lung Cancer. Molecular Cancer Therapeutics, 2011, 10, 637-647.	4.1	14
369	Unfolded Protein Response Is Required in nu/nu Mice Microvasculature for Treating Breast Tumor with Tunicamycin. Journal of Biological Chemistry, 2011, 286, 29127-29138.	3.4	77
370	EZH2 Regulates Neuronal Differentiation of Mesenchymal Stem Cells through PIP5K1C-dependent Calcium Signaling. Journal of Biological Chemistry, 2011, 286, 9657-9667.	3.4	61
371	CARMA3 is Crucial for EGFR-Induced Activation of NF-Î°B and Tumor Progression. Cancer Research, 2011, 71, 2183-2192.	0.9	83
372	Myocyte Enhancer Factor-2 Interacting Transcriptional Repressor (MITR) Is a Switch That Promotes Osteogenesis and Inhibits Adipogenesis of Mesenchymal Stem Cells by Inactivating Peroxisome Proliferator-activated Receptor Î³-2. Journal of Biological Chemistry, 2011, 286, 10671-10680.	3.4	55
373	Nuclear Translocation of Epidermal Growth Factor Receptor by Akt-dependent Phosphorylation Enhances Breast Cancer-resistant Protein Expression in Gefitinib-resistant Cells. Journal of Biological Chemistry, 2011, 286, 20558-20568.	3.4	154
374	Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatinâ€“Cytosine Deaminaseâ€“Uracil Phosphoribosyltransferase. Molecular Cancer Therapeutics, 2011, 10, 1327-1336.	4.1	21
375	APOBEC3G promotes liver metastasis in an orthotopic mouse model of colorectal cancer and predicts human hepatic metastasis. Journal of Clinical Investigation, 2011, 121, 4526-4536.	8.2	117
376	Abstract 1086: RHA plays an important role in EGFR-mediated gene transcription in cancer cells. , 2011, , .		0
377	Abstract 721: Putative molecular mechanism contributing AZD6244 resistance in lung cancer. , 2011, , .		0
378	Abstract 4710: p53 regulates epithelial-mesenchymal transition (EMT) and stem cell properties through modulation of miRNAs. , 2011, , .		1

#	Article	IF	Citations
379	Abstract 1438: Breast cancer metastasis suppressor 1 (BRMS1) suppresses attachment and spreading of breast cancer cells on 2D and 3D extracellular matrix components by altering focal adhesion-associated signaling. , 2011, , .		1
380	Abstract 4051: EGF receptor trafficking from the cell surface to the nucleus through the Golgi, ER, and nuclear envelope. , 2011, , .		0
381	Abstract 976: Hypoxic microenvironment promotes breast cancer stem cells through regulation of Polycomb protein expression. , 2011, , .		0
382	Abstract A57: The novel function of nuclear ErbB-2 in regulating transcription of rRNA genes. , 2011, , .		0
383	The roles of EZH2 in cell lineage commitment. American Journal of Translational Research (discontinued), 2011, 3, 243-50.	0.0	62
384	ARD1 Stabilization of TSC2 Suppresses Tumorigenesis Through the mTOR Signaling Pathway. Science Signaling, 2010, 3, ra9.	3.6	82
385	The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. Breast Cancer: Basic and Clinical Research, 2010, 4, 117822341000400.	1.1	199
386	Regulation of Tumor Angiogenesis by EZH2. Cancer Cell, 2010, 18, 185-197.	16.8	346
387	Recombinant Human Erythropoietin Antagonizes Trastuzumab Treatment of Breast Cancer Cells via Jak2-Mediated Src Activation and PTEN Inactivation. Cancer Cell, 2010, 18, 423-435.	16.8	129
388	Antitumor agents 270. Novel substituted 6-phenyl-4H-furo[3,2-c]pyran-4-one derivatives as potent and highly selective anti-breast cancer agents. Bioorganic and Medicinal Chemistry, 2010, 18, 803-808.	3.0	31
389	NF-Î²B signaling mediates the induction of MTA1 by hepatitis B virus transactivator protein HBx. Oncogene, 2010, 29, 1179-1189.	5.9	64
390	Nuclear trafficking of the epidermal growth factor receptor family membrane proteins. Oncogene, 2010, 29, 3997-4006.	5.9	199
391	Adenovirus 5 E1A enhances histone deacetylase inhibitors-induced apoptosis through Egr-1-mediated Bim upregulation. Oncogene, 2010, 29, 5619-5629.	5.9	28
392	TRIM24 links a non-canonical histone signature to breast cancer. Nature, 2010, 468, 927-932.	27.8	374
393	Deciphering the transcriptional complex critical for RhoA gene expression and cancer metastasis. Nature Cell Biology, 2010, 12, 457-467.	10.3	190
394	Activation of FOXO3a Is Sufficient to Reverse Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor Chemoresistance in Human Cancer. Cancer Research, 2010, 70, 4709-4718.	0.9	70
395	Downregulation of MicroRNA miR-520h by E1A Contributes to Anticancer Activity. Cancer Research, 2010, 70, 5096-5108.	0.9	58
396	Activation of Murine Double Minute 2 by Akt in Mammary Epithelium Delays Mammary Involution and Accelerates Mammary Tumorigenesis. Cancer Research, 2010, 70, 7684-7689.	0.9	17

#	Article	IF	Citations
397	Aurora Kinase A Promotes Ovarian Tumorigenesis through Dysregulation of the Cell Cycle and Suppression of BRCA2. Clinical Cancer Research, 2010, 16, 3171-3181.	7.0	106
398	The Translocon Sec61Î² Localized in the Inner Nuclear Membrane Transports Membrane-embedded EGF Receptor to the Nucleus. Journal of Biological Chemistry, 2010, 285, 38720-38729.	3.4	107
399	Blockade of Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase and Murine Double Minute Synergistically Induces Apoptosis in Acute Myeloid Leukemia via BH3-Only Proteins Puma and Bim. Cancer Research, 2010, 70, 2424-2434.	0.9	68
400	RNA helicase A is a DNA-binding partner for EGFR-mediated transcriptional activation in the nucleus. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 16125-16130.	7.1	95
401	Rapamycin Regulates Stearoyl CoA Desaturase 1 Expression in Breast Cancer. Molecular Cancer Therapeutics, 2010, 9, 2770-2784.	4.1	59
402	Vimentin Is a Novel Anti-Cancer Therapeutic Target; Insights from In Vitro and In Vivo Mice Xenograft Studies. PLoS ONE, 2010, 5, e10105.	2.5	166
403	Xenoestrogen-Induced Regulation of EZH2 and Histone Methylation via Estrogen Receptor Signaling to PI3K/AKT. Molecular Endocrinology, 2010, 24, 993-1006.	3.7	156
404	High speed digital protein interaction analysis using microfluidic single molecule detection system. Lab on A Chip, 2010, 10, 1793.	6.0	11
405	Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells. Breast Cancer Research, 2010, 12, R96.	5.0	97
406	Antitumor Agents. 272. Structureâ^'Activity Relationships and In Vivo Selective Anti-Breast Cancer Activity of Novel Neo-tanshinlactone Analogues. Journal of Medicinal Chemistry, 2010, 53, 2299-2308.	6.4	64
407	Antitumor Agents. 282. 2â€²-(R)-O-Acetylglaucarubinone, a Quassinoid from Odyendyea gabonensis As a Potential Anti-Breast and Anti-Ovarian Cancer Agent. Journal of Natural Products, 2010, 73, 1553-1558.	3.0	21
408	COPI-mediated retrograde trafficking from the Golgi to the ER regulates EGFR nuclear transport. Biochemical and Biophysical Research Communications, 2010, 399, 498-504.	2.1	116
409	Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. Biochemical and Biophysical Research Communications, 2010, 403, 103-107.	2.1	30
410	Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nature Reviews Clinical Oncology, 2010, 7, 98-107.	27.6	148
411	Rapid detection of two-protein interaction with a single fluorophore by using a microfluidic device. Analyst, The, 2010, 135, 2907.	3.5	9
412	Measurement of Protein 53 Diffusion Coefficient in Live HeLa Cells Using Raster Image Correlation Spectroscopy (RICS). Journal of Biomaterials and Nanobiotechnology, 2010, 01, 31-36.	0.5	6
413	Abstract 4017: Identifying Protein-Protein Interactions in Single Protein Complex level by Microchannel Device. , 2010, , .		0
414	Abstract 263: p38 MAPK is required for EGFR nuclear translocation. , 2010, , .		0

#	Article	IF	Citations
415	Physiological regulation of Akt activity and stability. American Journal of Translational Research (discontinued), 2010, 2, 19-42.	0.0	212
416	Arrest-defective-1 protein (ARD1): tumor suppressor or oncoprotein?. American Journal of Translational Research (discontinued), 2010, 2, 56-64.	0.0	17
417	CXCR4 Expression in Early Breast Cancer and Risk of Distant Recurrence. Oncologist, 2009, 14, 1182-1188.	3.7	59
418	Regulation of Breast Cancer Metastasis by Atypical Chemokine Receptors. Clinical Cancer Research, 2009, 15, 2951-2953.	7.0	3
419	Galectin-3 Mediates Nuclear Î²-Catenin Accumulation and Wnt Signaling in Human Colon Cancer Cells by Regulation of Glycogen Synthase Kinase-3Î² Activity. Cancer Research, 2009, 69, 1343-1349.	0.9	165
420	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Reverses Mesenchymal to Epithelial Phenotype and Inhibits Metastasis in Inflammatory Breast Cancer. Clinical Cancer Research, 2009, 15, 6639-6648.	7.0	113
421	p53 Acetylation Is Crucial for Its Transcription-independent Proapoptotic Functions. Journal of Biological Chemistry, 2009, 284, 11171-11183.	3.4	111
422	Genetic Variations in the PI3K/PTEN/AKT/mTOR Pathway Are Associated With Clinical Outcomes in Esophageal Cancer Patients Treated With Chemoradiotherapy. Journal of Clinical Oncology, 2009, 27, 857-871.	1.6	154
423	Crosstalk between Protease-activated Receptor 1 and Platelet-activating Factor Receptor Regulates Melanoma Cell Adhesion Molecule (MCAM/MUC18) Expression and Melanoma Metastasis. Journal of Biological Chemistry, 2009, 284, 28845-28855.	3.4	69
424	Nuclear Translocation of the Epidermal Growth Factor Receptor Family Membrane Tyrosine Kinase Receptors. Clinical Cancer Research, 2009, 15, 6484-6489.	7.0	157
425	EPOX Inhibits Angiogenesis by Degradation of Mcl-1 through ERK Inactivation. Clinical Cancer Research, 2009, 15, 4904-4914.	7.0	22
426	Expanding the arsenal: Metformin for the treatment of triple-negative breast cancer?. Cell Cycle, 2009, 8, 2681-2684.	2.6	22
427	Different Redox States in Malignant and Nonmalignant Esophageal Epithelial Cells and Differential Cytotoxic Responses to Bile Acid and Honokiol. Antioxidants and Redox Signaling, 2009, 11, 1083-1095.	5.4	36
428	A novel hTERT promoterâ€“driven E1A therapeutic for ovarian cancer. Molecular Cancer Therapeutics, 2009, 8, 2375-2382.	4.1	34
429	14-3-3Î¶ Overexpression Defines High Risk for Breast Cancer Recurrence and Promotes Cancer Cell Survival. Cancer Research, 2009, 69, 3425-3432.	0.9	175
430	ErbB2-Mediated Src and Signal Transducer and Activator of Transcription 3 Activation Leads to Transcriptional Up-Regulation of p21Cip1 and Chemoresistance in Breast Cancer Cells. Molecular Cancer Research, 2009, 7, 592-600.	3.4	54
431	A New Fork for Clinical Application: Targeting Forkhead Transcription Factors in Cancer. Clinical Cancer Research, 2009, 15, 752-757.	7.0	237
432	Expression of Autotaxin and Lysophosphatidic Acid Receptors Increases Mammary Tumorigenesis, Invasion, and Metastases. Cancer Cell, 2009, 15, 539-550.	16.8	332

#	Article	IF	Citations
433	Expression of Autotaxin and Lysophosphatidic Acid Receptors Increases Mammary Tumorigenesis, Invasion, and Metastases. Cancer Cell, 2009, 16, 172.	16.8	3
434	14-3-3Î¶ Cooperates with ErbB2 to Promote Ductal Carcinoma In Situ Progression to Invasive Breast Cancer by Inducing Epithelial-Mesenchymal Transition. Cancer Cell, 2009, 16, 195-207.	16.8	195
435	Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer. Molecular Carcinogenesis, 2009, 48, 610-617.	2.7	131
436	The suppression of MAD1 by AKTâ€mediated phosphorylation activates MAD1 target genes transcription. Molecular Carcinogenesis, 2009, 48, 1048-1058.	2.7	19
437	Oxygen sensor boosts growth factor signaling. Nature Medicine, 2009, 15, 246-247.	30.7	21
438	Cancer targeted gene therapy of BikDD inhibits orthotopic lung cancer growth and improves long-term survival. Oncogene, 2009, 28, 3286-3295.	5.9	35
439	Peptidyl-prolyl cis/trans isomerase Pin1 is critical for the regulation of PKB/Akt stability and activation phosphorylation. Oncogene, 2009, 28, 2436-2445.	5.9	78
440	Therapy-induced expression of NF-Î²B portends poor prognosis in patients with localized esophageal cancer undergoing preoperative chemoradiation. Ecological Management and Restoration, 2009, 22, 127-132.	0.4	15
441	Phosphorylation of ARD1 by IKKÎ² contributes to its destabilization and degradation. Biochemical and Biophysical Research Communications, 2009, 389, 156-161.	2.1	16
442	TNFÎ± induces HIF-1Î± expression through activation of IKKÎ². Biochemical and Biophysical Research Communications, 2009, 389, 640-644.	2.1	25
443	KEAP1 E3 Ligase-Mediated Downregulation of NF-Î²B Signaling by Targeting IKKÎ². Molecular Cell, 2009, 36, 131-140.	9.7	344
444	Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer. Journal of Clinical Oncology, 2009, 27, 3297-3302.	1.6	795
445	Induction of Akt Activity by Chemotherapy Confers Acquired Resistance. Journal of the Formosan Medical Association, 2009, 108, 180-194.	1.7	116
446	Optofluidic single molecule flow proteometry. Proceedings of SPIE, 2009, , .	0.8	0
447	Nuclear EGFR is required for cisplatin resistance and DNA repair. American Journal of Translational Research (discontinued), 2009, 1, 249-58.	0.0	66
448	Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Molecular Carcinogenesis, 2008, 47, 701-706.	2.7	249
449	Interferonâ€inducible protein IFIXÎ± inhibits cell invasion by upregulating the metastasis suppressor maspin. Molecular Carcinogenesis, 2008, 47, 739-743.	2.7	16
450	ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nature Cell Biology, 2008, 10, 138-148.	10.3	590

#	Article	IF	Citations
451	GSK-3Î² Targets Cdc25A for Ubiquitin-Mediated Proteolysis, and GSK-3Î² Inactivation Correlates with Cdc25A Overproduction in Human Cancers. Cancer Cell, 2008, 13, 36-47.	16.8	151
452	Survival of Cancer Cells Is Maintained by EGFR Independent of Its Kinase Activity. Cancer Cell, 2008, 13, 385-393.	16.8	432
453	Further Evidence for Expression and Function of the VEGF-C/VEGFR-3 Axis in Cancer Cells. Cancer Cell, 2008, 13, 557-560.	16.8	43
454	The VEGF-C/Flt-4 Axis Promotes Invasion and Metastasis of Cancer Cells. Cancer Cell, 2008, 14, 274-277.	16.8	0
455	An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer. Cancer Research, 2008, 68, 6084-6091.	0.9	916
456	Interplay among BRCA1, SIRT1, and Survivin during BRCA1-Associated Tumorigenesis. Molecular Cell, 2008, 32, 11-20.	9.7	334
457	The fabrication and testing of electrospun silica nanofiber membranes for the detection of proteins. Nanotechnology, 2008, 19, 445714.	2.6	32
458	Bile Acid Exposure Up-regulates Tuberous Sclerosis Complex 1/Mammalian Target of Rapamycin Pathway in Barrett's-Associated Esophageal Adenocarcinoma. Cancer Research, 2008, 68, 2632-2640.	0.9	58
459	Down-regulation of Myeloid Cell Leukemia-1 through Inhibiting Erk/Pin 1 Pathway by Sorafenib Facilitates Chemosensitization in Breast Cancer. Cancer Research, 2008, 68, 6109-6117.	0.9	167
460	Advances in Targeting IKK and IKK-Related Kinases for Cancer Therapy. Clinical Cancer Research, 2008, 14, 5656-5662.	7.0	102
461	Targeting YB-1 in HER-2 Overexpressing Breast Cancer Cells Induces Apoptosis via the mTOR/STAT3 Pathway and Suppresses Tumor Growth in Mice. Cancer Research, 2008, 68, 8661-8666.	0.9	109
462	Correction: Reduced P27kip1 and Trastuzumab Resistance. Cancer Research, 2008, 68, 10005-10005.	0.9	2
463	Nanofluidic Devices for Single Molecule Identification. Journal of Photopolymer Science and Technology = [Fotoporima Konwakai Shi], 2008, 21, 531-536.	0.3	2
464	All Roads Lead to mTOR: Integrating Inflammation and Tumor Angiogenesis. Cell Cycle, 2007, 6, 3011-3014.	2.6	104
465	ErbB-2 Induces the Cyclin D1 Gene in Prostate Epithelial Cells In vitro and In vivo. Cancer Research, 2007, 67, 4364-4372.	0.9	36
466	Epidermal Growth Factor Receptor Cooperates with Signal Transducer and Activator of Transcription 3 to Induce Epithelial-Mesenchymal Transition in Cancer Cells via Up-regulation of TWIST Gene Expression. Cancer Research, 2007, 67, 9066-9076.	0.9	605
467	Degradation of Mcl-1 by Î²-TrCP Mediates Glycogen Synthase Kinase 3-Induced Tumor Suppression and Chemosensitization. Molecular and Cellular Biology, 2007, 27, 4006-4017.	2.3	348
468	Characterization of a Novel Tripartite Nuclear Localization Sequence in the EGFR Family. Journal of Biological Chemistry, 2007, 282, 10432-10440.	3.4	208

#	Article	IF	Citations
469	Crystal structure of the human FOXO3a-DBD/DNA complex suggests the effects of post-translational modification. Nucleic Acids Research, 2007, 35, 6984-6994.	14.5	178
470	Clinical Biology of Esophageal Adenocarcinoma after Surgery Is Influenced by Nuclear Factor-Î¹B Expression. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1200-1205.	2.5	25
471	Kruì^ppel-Like Factor 8 Induces Epithelial to Mesenchymal Transition and Epithelial Cell Invasion. Cancer Research, 2007, 67, 7184-7193.	0.9	175
472	Myeloid Cell Leukemia-1 Inversely Correlates with Glycogen Synthase Kinase-3Î² Activity and Associates with Poor Prognosis in Human Breast Cancer. Cancer Research, 2007, 67, 4564-4571.	0.9	171
473	Rapamycin regulates the phosphorylation of rictor. Biochemical and Biophysical Research Communications, 2007, 362, 330-333.	2.1	55
474	IKKÎ² Suppression of TSC1 Links Inflammation and Tumor Angiogenesis via the mTOR Pathway. Cell, 2007, 130, 440-455.	28.9	585
475	Î¹B Kinase Promotes Tumorigenesis through Inhibition of Forkhead FOXO3a. Cell, 2007, 129, 1427-1428.	28.9	3
476	Phosphorylation of CBP by IKKÎ± Promotes Cell Growth by Switching the Binding Preference of CBP from p53 to NF-Î¹B. Molecular Cell, 2007, 26, 75-87.	9.7	212
477	Mechanisms of synthetic serine protease inhibitor (FUT-175)-mediated cell death. Cancer, 2007, 109, 2142-2153.	4.1	39
478	Antitumor agents. 258. Syntheses and evaluation of dietary antioxidantâ€"taxoid conjugates as novel cytotoxic agents. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 5204-5209.	2.2	49
479	Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelialâ€"mesenchymal transition. Oncogene, 2007, 26, 7859-7871.	5.9	183
480	The role of the VEGF-C/VEGFR-3 axis in cancer progression. British Journal of Cancer, 2007, 96, 541-545.	6.4	211
481	The VEGF-C/Flt-4 Axis Promotes Invasion and Metastasis of Cancer Cells. Cancer Cell, 2007, 11, 207.	16.8	0
482	Targeted Expression of BikDD Eradicates Pancreatic Tumors in Noninvasive Imaging Models. Cancer Cell, 2007, 12, 52-65.	16.8	71
483	A New Mutational aktivation in the PI3K Pathway. Cancer Cell, 2007, 12, 104-107.	16.8	230
484	Molecular Mechanisms in Barrettâ€™s Metaplasia and Its Progression. Seminars in Oncology, 2007, 34, S2-S6.	2.2	24
485	Breast cancer brain metastases. Cancer and Metastasis Reviews, 2007, 26, 635-643.	5.9	93
486	Novel Approaches for Chemosensitization of Breast Cancer Cells: The E1A Story. Advances in Experimental Medicine and Biology, 2007, 608, 144-169.	1.6	21

#	Article	IF	Citations
487	Trials and Tribulations in Developing Clinical Trials of Gene Therapy. , 2007, , 387-398.		0
488	Development of Therapeutic Genes for Breast Cancer Treatment. , 2007, , 435-446.		0
489	Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nature Clinical Practice Oncology, 2006, 3, 269-280.	4.3	858
490	Electrospinning of silica nanochannels for single molecule detection. Applied Physics Letters, 2006, 88, 033106.	3.3	55
491	Suppression of pancreatic tumor progression by systemic delivery of a pancreatic-cancer-specific promoter driven Bik mutant. Cancer Letters, 2006, 236, 58-63.	7.2	25
492	Cytoplasmic expression of p21CIP1/WAF1 is correlated with IKKÎ² overexpression in human breast cancers. International Journal of Oncology, 2006, 29, 1103.	3.3	4
493	Tyrosine phosphorylation controls PCNA function through protein stability. Nature Cell Biology, 2006, 8, 1359-1368.	10.3	277
494	Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. British Journal of Cancer, 2006, 94, 184-188.	6.4	254
495	An attenuated Salmonella oral DNA vaccine prevents the growth of hepatocellular carcinoma and colon cancer that express Î±-fetoprotein. Cancer Gene Therapy, 2006, 13, 746-752.	4.6	34
496	Mutant Bik expression mediated by the enhanced minimal topoisomerase IIÎ± promoter selectively suppressed breast tumors in an animal model. Cancer Gene Therapy, 2006, 13, 706-719.	4.6	14
497	EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. Breast Cancer Research and Treatment, 2006, 95, 211-218.	2.5	209
498	Expression of PEA3 and Lack of Correlation Between PEA3 and HER-2/neu Expression in Breast Cancer. Breast Cancer Research and Treatment, 2006, 98, 295-301.	2.5	17
499	The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell, 2006, 9, 209-223.	16.8	308
500	Nuclearâ€cytoplasmic transport of EGFR involves receptor endocytosis, importin Î²1 and CRM1. Journal of Cellular Biochemistry, 2006, 98, 1570-1583.	2.6	210
501	Inefficient proteasomal-degradation pathway stabilizes AP-2Î± and activates HER-2/neugene in breast cancer. International Journal of Cancer, 2006, 118, 802-811.	5.1	25
502	Direct sequencing analysis of transmembrane region of human neu gene by polymerase chain reaction. Molecular Carcinogenesis, 2006, 3, 198-201.	2.7	25
503	Coâ€regulation of Bâ€Myb expression by E2F1 and EGF receptor. Molecular Carcinogenesis, 2006, 45, 10-17.	2.7	157
504	Nuclear translocation of the pro-apoptotic Bcl-2 family member Bok induces apoptosis. Molecular Carcinogenesis, 2006, 45, 73-83.	2.7	34

#	Article	IF	Citations
505	Antitumor activity of an Ets protein, PEA3, in breast cancer cell lines MDA-MB-361DYT2 and BT474M1. Molecular Carcinogenesis, 2006, 45, 667-675.	2.7	21
506	AIM2 suppresses human breast cancer cell proliferation in vitro and mammary tumor growth in a mouse model. Molecular Cancer Therapeutics, 2006, 5, 1-7.	4.1	129
507	Advances in Targeting Human Epidermal Growth Factor Receptor-2 Signaling for Cancer Therapy: Fig. 1.. Clinical Cancer Research, 2006, 12, 6326-6330.	7.0	114
508	Synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cells. Molecular Cancer Therapeutics, 2006, 5, 317-328.	4.1	68
509	Novel Signaling Pathways in Breast Cancer. , 2006, , 823-839.		2
510	MDM2 Promotes Cell Motility and Invasiveness by Regulating E-Cadherin Degradation. Molecular and Cellular Biology, 2006, 26, 7269-7282.	2.3	176
511	Endostatin-Cytosine Deaminase Fusion Protein Suppresses Tumor Growth by Targeting Neovascular Endothelial Cells. Cancer Research, 2006, 66, 378-384.	0.9	17
512	A novel CRM1â€dependent nuclear export signal in adenoviral E1A protein regulated by phosphorylation. FASEB Journal, 2006, 20, 2603-2605.	0.5	10
513	1002. L1 Cell Adhesion Molecule, a Novel Target of Prostate Cancer Gene Therapy. Molecular Therapy, 2006, 13, S386.	8.2	0
514	Breast Cancer Gene Therapy. , 2006, , 705-740.		1
515	Cytoplasmic/Nuclear Shuttling and Tumor Progression. Annals of the New York Academy of Sciences, 2005, 1059, 11-15.	3.8	35
516	Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell, 2005, 7, 575-589.	16.8	463
517	Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry. Breast Cancer Research and Treatment, 2005, 89, 149-157.	2.5	98
518	Improved peak detection and quantification of mass spectrometry data acquired from surface-enhanced laser desorption and ionization by denoising spectra with the undecimated discrete wavelet transform. Proteomics, 2005, 5, 4107-4117.	2.2	293
519	Endosomal Transport of ErbB-2: Mechanism for Nuclear Entry of the Cell Surface Receptor. Molecular and Cellular Biology, 2005, 25, 11005-11018.	2.3	214
520	Bcl-2 Antisense Oligonucleotide Overcomes Resistance to E1A Gene Therapy in a Low HER2-Expressing Ovarian Cancer Xenograft Model. Cancer Research, 2005, 65, 8406-8413.	0.9	27
521	The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers. Endocrine-Related Cancer, 2005, 12, 511-532.	3.1	62
522	Role of Glycogen Synthase Kinase 3Î² in Rapamycin-Mediated Cell Cycle Regulation and Chemosensitivity. Cancer Research, 2005, 65, 1961-1972.	0.9	98

#	Article	IF	Citations
523	A Hypoxia-Independent Hypoxia-Inducible Factor-1 Activation Pathway Induced by Phosphatidylinositol-3 Kinase/Akt in HER2 Overexpressing Cells. Cancer Research, 2005, 65, 3257-3263.	0.9	96
524	Role of I?B kinase in tumorigenesis. Future Oncology, 2005, 1, 67-78.	2.4	34
525	Targeting ECMâ€"Integrin Interaction with Liposome-Encapsulated Small Interfering RNAs Inhibits the Growth of Human Prostate Cancer in a Bone Xenograft Imaging Model. Molecular Therapy, 2005, 12, 634-643.	8.2	82
526	Signaling Intricacies Take Center Stage in Cancer Cells: Figure 1.. Cancer Research, 2005, 65, 2511-2515.	0.9	53
527	Emodin Down-Regulates Androgen Receptor and Inhibits Prostate Cancer Cell Growth. Cancer Research, 2005, 65, 2287-2295.	0.9	155
528	When all the colonies are blue. Cancer Biology and Therapy, 2005, 4, 612-614.	3.4	0
529	Wnt, Hedgehog, and Snail: Sister Pathways That Control by GSK-3beta and beta-Trcp in the Regulation of Metastasis. Cell Cycle, 2005, 4, 772-776.	2.6	110
530	Akt-Mediated Phosphorylation of EZH2 Suppresses Methylation of Lysine 27 in Histone H3. Science, 2005, 310, 306-310.	12.6	497
531	Erk Associates with and Primes GSK-3Î² for Its Inactivation Resulting in Upregulation of Î²-Catenin. Molecular Cell, 2005, 19, 159-170.	9.7	535
532	Cancerâ€Specific Gene Therapy. Advances in Genetics, 2005, 54, 233-255.	1.8	59
533	E1A Sensitizes Cancer Cells to TRAIL-Induced Apoptosis through Enhancement of Caspase Activation. Molecular Cancer Research, 2005, 3, 219-226.	3.4	19
534	Antimetastasis. , 2005, , 287-298.		0
535	Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Research, 2005, 65, 338-48.	0.9	199
536	Delivery of DNA to Tumor Cells Using Cationic Liposomes. , 2004, 245, 125-136.		3
537	P27kip1 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells. Cancer Research, 2004, 64, 3981-3986.	0.9	283
538	Phosphorylation/Cytoplasmic Localization of p21Cip1/WAF1 Is Associated with HER2/neu Overexpression and Provides a Novel Combination Predictor for Poor Prognosis in Breast Cancer Patients. Clinical Cancer Research, 2004, 10, 3815-3824.	7.0	150
539	Selective Activation of Ceruloplasmin Promoter in Ovarian Tumors. Cancer Research, 2004, 64, 1788-1793.	0.9	32
540	A New Role of Protein Phosphatase 2A in Adenoviral E1A Protein-Mediated Sensitization to Anticancer Drug-Induced Apoptosis in Human Breast Cancer Cells. Cancer Research, 2004, 64, 5938-5942.	0.9	52

#	Article	IF	Citations
541	Determinants of Rapamycin Sensitivity in Breast Cancer Cells. Clinical Cancer Research, 2004, 10, 1013-1023.	7.0	269
542	Finding the bEST routes to cancer. Cancer Biology and Therapy, 2004, 3, 1090-1091.	3.4	8
543	Adenoviral E1A Targets Mdm4 to Stabilize Tumor Suppressor p53. Cancer Research, 2004, 64, 9080-9085.	0.9	34
544	Dual regulation of Snail by GSK-3Î²-mediated phosphorylation in control of epithelialâ€“mesenchymal transition. Nature Cell Biology, 2004, 6, 931-940.	10.3	1,459
545	Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a nonviral-mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer. Cancer Gene Therapy, 2004, 11, 594-602.	4.6	42
546	Cancer-specific activation of the survivin promoter and its potential use in gene therapy. Cancer Gene Therapy, 2004, 11, 740-747.	4.6	110
547	A delayed chemically induced tumorigenesis in Brca2 mutant mice. Oncogene, 2004, 23, 1896-1901.	5.9	11
548	Upregulation of IKKÎ±/IKKÎ² by integrin-linked kinase is required for HER2/neu-induced NF-Î¹B antiapoptotic pathway. Oncogene, 2004, 23, 3883-3887.	5.9	41
549	Association between ductal fluid proteomic expression profiles and the presence of lymph node metastases in women with breast cancer. Surgery, 2004, 136, 1061-1069.	1.9	30
550	PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell, 2004, 6, 117-127.	16.8	1,693
551	Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell, 2004, 6, 251-261.	16.8	261
552	Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell, 2004, 6, 459-469.	16.8	497
553	STK15/Aurora-A expression in primary breast tumors is correlated with nuclear grade but not with prognosis. Cancer, 2004, 100, 12-19.	4.1	74
554	Crossregulation of NF-?B by the APC/GSK-3?/?-catenin pathway. Molecular Carcinogenesis, 2004, 39, 139-146.	2.7	84
555	Î¹B Kinase Promotes Tumorigenesis through Inhibition of Forkhead FOXO3a. Cell, 2004, 117, 225-237.	28.9	823
556	Targeting Mammalian Target of Rapamycin Synergistically Enhances Chemotherapy-Induced Cytotoxicity in Breast Cancer Cells. Clinical Cancer Research, 2004, 10, 7031-7042.	7.0	303
557	The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells. Cancer Research, 2004, 64, 2343-2346.	0.9	535
558	Discussion: Molecular Therapeutics and Pharmacogenomics. Gynecologic Oncology, 2003, 88, S93-S96.	1.4	2

#	Article	IF	Citations
559	Dysregulation of cellular signaling by HER2 in breast cancer. Seminars in Oncology, 2003, 30, 38-48.	2.2	106
560	Î²-catenin nuclear localization is associated with grade in ovarian serous carcinoma. Gynecologic Oncology, 2003, 88, 363-368.	1.4	48
561	Prostate-specific antitumor activity by probasin promoter-directed p202 expression. Molecular Carcinogenesis, 2003, 37, 130-137.	2.7	13
562	Quality Control and Peak Finding for Proteomics Data Collected from Nipple Aspirate Fluid by Surface-Enhanced Laser Desorption and Ionization. Clinical Chemistry, 2003, 49, 1615-1623.	3.2	203
563	The adenoviral E1A induces p21WAF1/CIP1 expression in cancer cells. Biochemical and Biophysical Research Communications, 2003, 305, 1099-1104.	2.1	17
564	Strategies to target HER2/neu overexpression for cancer therapy. Drug Resistance Updates, 2003, 6, 129-136.	14.4	78
565	Regulation of the Activity of p38 Mitogen-Activated Protein Kinase by Akt in Cancer and Adenoviral Protein E1A-Mediated Sensitization to Apoptosis. Molecular and Cellular Biology, 2003, 23, 6836-6848.	2.3	101
566	Adenovirus type 5 E1A sensitizes hepatocellular carcinoma cells to gemcitabine. Cancer Research, 2003, 63, 6229-36.	0.9	36
567	Enhancement of Bik antitumor effect by Bik mutants. Cancer Research, 2003, 63, 7630-3.	0.9	44
568	External control of Her2 expression and cancer cell growth by targeting a Ras-linked coactivator. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 12747-12752.	7.1	63
569	Transcription-coupled DNA Repair Is Genomic Context-dependent. Journal of Biological Chemistry, 2002, 277, 12777-12783.	3.4	24
570	Preferential DNA Damage and Poor Repair Determine ras Gene Mutational Hotspot in Human Cancer. Journal of the National Cancer Institute, 2002, 94, 1527-1536.	6.3	98
571	Generation and characterization of androgen receptor knockout (ARKO) mice: An in vivo model for the study of androgen functions in selective tissues. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 13498-13503.	7.1	591
572	Phosphorylation on Tyrosine-15 of p34Cdc2 by ErbB2 Inhibits p34Cdc2 Activation and Is Involved in Resistance to Taxol-Induced Apoptosis. Molecular Cell, 2002, 9, 993-1004.	9.7	124
573	HER-2/Neu signaling and therapeutic approaches in breast cancer. Breast Disease, 2002, 15, 13-24.	0.8	10
574	Novel targets of Akt, p21, and MDM2. Seminars in Oncology, 2002, 29, 62-70.	2.2	25
575	Î²-catenin interacts with and inhibits NF-ÎºB in human colon and breast cancer. Cancer Cell, 2002, 2, 323-334.	16.8	336
576	HER2/neu in the management of invasive breast cancer. Journal of the American College of Surgeons, 2002, 194, 488-501.	0.5	39

#	Article	IF	Citations
577	A multicenter phase II study of tgDCC-E1A for the intratumoral treatment of patients with recurrent head and neck squamous cell carcinoma. Head and Neck, 2002, 24, 661-669.	2.0	67
578	Ceramide does not act as a general second messenger for ultraviolet-induced apoptosis. Oncogene, 2002, 21, 44-52.	5.9	11
579	Akt is required for Axl-Gas6 signaling to protect cells from E1A-mediated apoptosis. Oncogene, 2002, 21, 329-336.	5.9	76
580	Her2/neu induces all-transretinoic acid (ATRA) resistance in breast cancer cells. Oncogene, 2002, 21, 5224-5232.	5.9	65
581	Role for the double-stranded RNA activated protein kinase PKR in E2F-1-induced apoptosis. Oncogene, 2002, 21, 6278-6288.	5.9	40
582	The suppression of colon cancer cell growth in nude mice by targetingÎ²-catenin/TCF pathway. Oncogene, 2002, 21, 8340-8346.	5.9	36
583	Localizing the EGF receptor - Reply. Nature Cell Biology, 2002, 4, E22-E23.	10.3	9
584	E1A Cancer Gene Therapy. , 2002, , 465-477.		4
585	Novel targets of Akt, p21, and MDM2. Seminars in Oncology, 2002, 29, 62-70.	2.2	119
586	Systemic tumor suppression by the proapoptotic gene bik. Cancer Research, 2002, 62, 8-12.	0.9	236
587	The NH(2)-terminal and conserved region 2 domains of adenovirus E1A mediate two distinct mechanisms of tumor suppression. Cancer Research, 2002, 62, 346-50.	0.9	18
588	Expression profile of tyrosine kinases in breast cancer. Clinical Cancer Research, 2002, 8, 361-7.	7.0	114
589	Automated electrorotation to reveal dielectric variations related to HER-2/neu overexpression in MCF-7 sublines. Clinical Cancer Research, 2002, 8, 615-9.	7.0	49
590	Inhibition of cancer cell growth by BRCA2. Cancer Research, 2002, 62, 1311-4.	0.9	38
591	Proapoptotic and antitumor activities of adenovirus-mediated p202 gene transfer. Clinical Cancer Research, 2002, 8, 3290-7.	7.0	15
592	Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. Cancer Research, 2002, 62, 5703-10.	0.9	85
593	Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene. Cancer Research, 2002, 62, 6712-6.	0.9	45
594	E1A Is an Oncogene and May Immortalize Normal Cells, Especially in Combination With Other Oncoproteins. Journal of Clinical Oncology, 2001, 19, 4183-4184.	1.6	3

#	Article	IF	Citations
595	Cationic Liposome-MediatedE1AGene Transfer to Human Breast and Ovarian Cancer Cells and Its Biologic Effects: A Phase I Clinical Trial. Journal of Clinical Oncology, 2001, 19, 3422-3433.	1.6	207
596	E1A: Tumor suppressor or oncogene? Preclinical and clinical investigations ofE1A gene therapy. Breast Cancer, 2001, 8, 285-293.	2.9	20
597	Correlation of p27 protein expression with HER-2/neu expression in breast cancer. Molecular Carcinogenesis, 2001, 30, 169-175.	2.7	45
598	Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nature Cell Biology, 2001, 3, 802-808.	10.3	950
599	HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nature Cell Biology, 2001, 3, 973-982.	10.3	850
600	Transcriptional upregulation and activation of p55Cdc via p34cdc2 in Taxol-induced apoptosis. Oncogene, 2001, 20, 2537-2543.	5.9	20
601	p27 Kip1 inhibits HER2/neu-mediated cell growth and tumorigenesis. Oncogene, 2001, 20, 3695-3702.	5.9	51
602	DOC-2/hDab-2 inhibits ILK activity and induces anoikis in breast cancer cells through an Akt-independent pathway. Oncogene, 2001, 20, 6960-6964.	5.9	51
603	Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nature Cell Biology, 2001, 3, 245-252.	10.3	999
604	Targeting HER2: Recent developments and future directions for breast cancer patients. Seminars in Oncology, 2001, 28, 21-29.	2.2	33
605	HER2 overexpression and cancer targeting. Seminars in Oncology, 2001, 28, 115-124.	2.2	49
606	Effectiveness of water soluble poly(L-glutamic acid)-camptothecin conjugate against resistant human lung cancer xenografted in nude mice. International Journal of Oncology, 2001, 18, 331-6.	3.3	19
607	Hyaluronan Promotes CD44v3-Vav2 Interaction with Grb2-p185HER2 and Induces Rac1 and Ras Signaling during Ovarian Tumor Cell Migration and Growth. Journal of Biological Chemistry, 2001, 276, 48679-48692.	3.4	168
608	HER2 overexpression and cancer targeting. Seminars in Oncology, 2001, 28, 115-124.	2.2	39
609	Targeting HER2: Recent developments and future directions for breast cancer patients. Seminars in Oncology, 2001, 28, 21-29.	2.2	104
610	Suppressing HER2/neu-Mediated Cell Transformation by Transcriptional Repressors. Breast Disease, 2000, 11, 133-144.	0.8	6
611	Role of erbB2 in breast cancer chemosensitivity. BioEssays, 2000, 22, 673-680.	2.5	106
612	The Ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis. Nature Medicine, 2000, 6, 189-195.	30.7	154

#	Article	IF	Citations
613	Adenovirus-mediated N5 gene transfer inhibits tumor cell proliferation by induction of apoptosis. Cancer Gene Therapy, 2000, 7, 985-990.	4.6	6
614	High tumoral maspin expression is associated with improved survival of patients with oral squamous cell carcinoma. Oncogene, 2000, 19, 2398-2403.	5.9	137
615	Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene, 2000, 19, 6115-6121.	5.9	363
616	Grb2 downregulation leads to Akt inactivation in heregulin-stimulated and ErbB2-overexpressing breast cancer cells. Oncogene, 2000, 19, 6271-6276.	5.9	38
617	Oncogenic Signals of HER-2/neu in Regulating the Stability of the Cyclin-dependent Kinase Inhibitor p27. Journal of Biological Chemistry, 2000, 275, 24735-24739.	3.4	113
618	HER-2/neu Blocks Tumor Necrosis Factor-induced Apoptosis via the Akt/NF-Î¹B Pathway. Journal of Biological Chemistry, 2000, 275, 8027-8031.	3.4	328
619	Regulatable Expression of p21-activated Kinase-1 Promotes Anchorage-independent Growth and Abnormal Organization of Mitotic Spindles in Human Epithelial Breast Cancer Cells. Journal of Biological Chemistry, 2000, 275, 36238-36244.	3.4	226
620	Î²-Catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 4262-4266.	7.1	731
621	Cyclin D1 Is Required for Transformation by Activated Neu and Is Induced through an E2F-Dependent Signaling Pathway. Molecular and Cellular Biology, 2000, 20, 672-683.	2.3	342
622	E1A Sensitizes Cells to Tumor Necrosis Factor-induced Apoptosis through Inhibition of IÎ¹B Kinases and Nuclear Factor Î¹B Activities. Journal of Biological Chemistry, 1999, 274, 21495-21498.	3.4	89
623	Reduced growth rate and transformation phenotype of the prostate cancer cells by an interferon-inducible protein, p202. Oncogene, 1999, 18, 807-811.	5.9	40
624	Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells. Oncogene, 1999, 18, 1325-1332.	5.9	62
625	Collagen-homology domainâ€‰1 deletion mutant of Shc suppresses transformation mediated by neu through a MAPK-independent pathway. Oncogene, 1999, 18, 2617-2626.	5.9	6
626	Inhibition of focal contact formation in cells transformed byp185neu. Molecular Carcinogenesis, 1999, 25, 150-154.	2.7	9
627	Chemo-signal therapy, an emerging new approach to modify drug resistance in breast cancer. Cancer Treatment Reviews, 1999, 25, 271-277.	7.7	21
628	The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. Oncogene, 1999, 18, 7034-7045.	5.9	288
629	Axl-Gas6 Interaction Counteracts E1A-Mediated Cell Growth Suppression and Proapoptotic Activity. Molecular and Cellular Biology, 1999, 19, 8075-8082.	2.3	61
630	Targeting HER-2/neu-Overexpressing Cancer Cells with Transcriptional Repressor Genes Delivered by Cationic Liposome. , 1999, , 357-377.		6

#	Article	IF	Citations
631	Translational Research in Breast Cancer. , 1999, , 345-356.		0
632	The erbB2 gene as a cancer therapeutic target and the tumor- and metastasis-suppressing function of E1A. , 1998, 17, 195-202.		27
633	Safety study and characterization of E1Aâ€“liposome complex gene-delivery protocol in an ovarian cancer model. Gene Therapy, 1998, 5, 1538-1544.	4.5	47
634	Recombinant PML adenovirus suppresses growth and tumorigenicity of human breast cancer cells by inducing G1 cell cycle arrest and apoptosis. Oncogene, 1998, 16, 1839-1849.	5.9	92
635	Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. Oncogene, 1998, 16, 2087-2094.	5.9	122
636	Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties. Oncogene, 1998, 16, 2855-2863.	5.9	108
637	Adenovirus 5 E1A-mediated tumor suppression associated with E1A-mediated apoptosis in vivo. Oncogene, 1998, 17, 2167-2175.	5.9	64
638	Characterization of BRCA2: temperature sensitivity of detection and cell-cycle regulated expression. Oncogene, 1998, 17, 2377-2381.	5.9	16
639	Preclinical and clinical study of HER-2/neu-targeting cancer gene therapy. Advanced Drug Delivery Reviews, 1998, 30, 219-227.	13.7	27
640	A novel splice variant ofHER2 with increased transformation activity. Molecular Carcinogenesis, 1998, 23, 62-68.	2.7	125
641	Overexpression of ErbB2 Blocks Taxol-Induced Apoptosis by Upregulation of p21Cip1, which Inhibits p34Cdc2 Kinase. Molecular Cell, 1998, 2, 581-591.	9.7	335
642	A Phase I Multicenter Study of E1A Gene Therapy for Patients with Metastatic Breast Cancer and Epithelial Ovarian Cancer That Overexpresses HER-2/neu or Epithelial Ovarian Cancer. M.D. Anderson Cancer Center, Houston, Texas. Human Gene Therapy, 1998, 9, 1775-1798.	2.7	46
643	IKKÎ² suppression of TSC1 function links the mTOR pathway with insulin resistance. International Journal of Molecular Medicine, 1998, 22, 633-8.	4.0	66
644	A novel splice variant of HER2 with increased transformation activity. , 1998, 23, 62.		2
645	Enhanced MDM2 Oncoprotein Expression in Soft Tissue Sarcoma: Several Possible Regulatory Mechanisms. Sarcoma, 1997, 1, 23-29.	1.3	7
646	Involvement of Co-activator p300 in the Transcriptional Regulation of the HER-2/neu Gene. Journal of Biological Chemistry, 1997, 272, 6101-6104.	3.4	43
647	Interaction between the Adhesion Receptor, CD44, and the Oncogene Product, p185 , Promotes Human Ovarian Tumor Cell Activation. Journal of Biological Chemistry, 1997, 272, 27913-27918.	3.4	215
648	Inhibition of Nuclear Factor-Î¹B Activity Is Involved in E1A-mediated Sensitization of Radiation-induced Apoptosis. Journal of Biological Chemistry, 1997, 272, 32739-32742.	3.4	105

#	Article	IF	Citations
649	Cross-reactivity of C219 Anti-p170mdr-1 Antibody With p185c-erbB2 in Breast Cancer Cells: Cautions on Evaluating p170mdr-1. Journal of the National Cancer Institute, 1997, 89, 1524-1529.	6.3	39
650	Mitosis-specific Negative Regulation of Epidermal Growth Factor Receptor, Triggered by a Decrease in Ligand Binding and Dimerization, Can Be Overcome by Overexpression of Receptor. Journal of Biological Chemistry, 1997, 272, 18656-18665.	3.4	54
651	Changes inBRCA2Expression during Progression of the Cell Cycle. Biochemical and Biophysical Research Communications, 1997, 234, 247-251.	2.1	30
652	Safety studies of the intraperitoneal injection of E1Aâ€“liposome complex in mice. Gene Therapy, 1997, 4, 238-243.	4.5	41
653	The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer. Oncogene, 1997, 14, 561-568.	5.9	81
654	Suppression of tumorigenicity of breast cancer cells by an epithelial cell adhesion molecule (C-CAM1): the adhesion and growth suppression are mediated by different domains. Oncogene, 1997, 14, 1697-1704.	5.9	94
655	Mapping of adenovirus 5 E1A domains responsible for suppression of neu-mediated transformation via transcriptional repression of neu. Oncogene, 1997, 14, 1965-1971.	5.9	26
656	Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. Oncogene, 1997, 15, 953-960.	5.9	86
657	Involvement of cdc2-mediated phosphorylation in the cell cycle-dependent regulation of p185neu. Oncogene, 1997, 15, 2633-2641.	5.9	9
658	Molecular profile of advanced-stage transitional cell carcinoma of the ovary. American Journal of Obstetrics and Gynecology, 1997, 177, 120-125.	1.3	9
659	Length of the Linking Domain of Human pro-Tumor Necrosis Factor Determines the Cleavage Processing. Biochemistry, 1996, 35, 8226-8233.	2.5	38
660	In VitroSynthesis of an N-myristoylated Fusion Protein That Binds to the Liposomal Surface. Archives of Biochemistry and Biophysics, 1996, 326, 179-184.	3.0	16
661	p66Shcisoform Down-Regulated and Not Required for HER-2/neu Signaling Pathway in Human Breast Cancer Cell Lines withHER-2/neuOverexpression. Biochemical and Biophysical Research Communications, 1996, 221, 140-145.	2.1	26
662	Identification of a Specific DNA Region Required for Enhanced Transcription of HER2/neuin the MDA-MB453 Breast Cancer Cell Line. DNA and Cell Biology, 1996, 15, 749-757.	1.9	12
663	Human pro-Tumor Necrosis Factor Is a Homotrimer. Biochemistry, 1996, 35, 8216-8225.	2.5	108
664	Cell cycle-dependent regulation of p185neu: a relationship between disruption of this regulation and transformation.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 1092-1096.	7.1	24
665	Human Pro-Tumor Necrosis Factor: Molecular Determinants of Membrane Translocation, Sorting, and Maturation. Molecular and Cellular Biology, 1995, 15, 6398-6405.	2.3	27
666	Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature, 1995, 378, 394-398.	27.8	1,165

#	Article	IF	Citations
667	ADP-Ribosylation Inhibitors Inhibit Cellular RNA Synthesis but Do Not Affect Expression of Manganous Superoxide Dismutase or Heat Shock Protein 70 in Tumor Necrosis Factor Î±Sensitive and -Resistant Tumor Cells. Journal of Interferon and Cytokine Research, 1995, 15, 791-797.	1.2	0
668	Dominant-negative Mutants of Grb2 Induced Reversal of the Transformed Phenotypes Caused by the Point Mutation-activated Rat HER-2/Neu. Journal of Biological Chemistry, 1995, 270, 30717-30724.	3.4	42
669	HER-2/neu Oncogene Characterization in Head and Neck Squamous Cell Carcinoma. JAMA Otolaryngology, 1995, 121, 1265-1270.	1.2	79
670	RODENT P53 SUPPRESSES THE TRANSFORMING ACTIVITY OF THE ACTIVATED NEU ONCOGENE BY MODULATING THE BASAL PROMOTER ACTIVITY OF NEU. International Journal of Oncology, 1995, 6, 1087-92.	3.3	2
671	Enhanced Chemoresistance by Elevation of p185neu Levels in HER-2/neu-Transfected Human Lung Cancer Cells. Journal of the National Cancer Institute, 1995, 87, 682-684.	6.3	96
672	HER-2/neu-targeting gene therapy-a review. Gene, 1995, 159, 65-71.	2.2	67
673	MECHANISMS OF DEREGULATED HER2/NEU EXPRESSION IN BREAST-CANCER CELL-LINES. International Journal of Oncology, 1994, 4, 599-608.	3.3	8
674	COMPLEX REGULATION OF THE ADENOVIRUS E2 PROMOTER BY THE VIRAL ONCOPROTEINS E1A AND E7 AND TUMOR-SUPPRESSOR RB. International Journal of Oncology, 1994, 4, 109-15.	3.3	1
675	HER2 NEU OVEREXPRESSION COUNTERACTS THE GROWTH EFFECTS OF C-MYC IN BREAST-CANCER CELLS. International Journal of Oncology, 1994, 4, 965-9.	3.3	1
676	Greater Enhancement of Chemosensitivity by Caffeine in High-p185neu-Expressing Human Non-Small-Cell Lung Cancer Cell Lines. Journal of the National Cancer Institute, 1994, 86, 1018-1020.	6.3	9
677	Triplex formation at the rat neu oncogene promoter. Gene, 1994, 149, 109-114.	2.2	10
678	Nuclear Localization of P185neu Tyrosine Kinase and Its Association with Transcriptional Transactivation. Biochemical and Biophysical Research Communications, 1994, 203, 1589-1598.	2.1	119
679	Hyperthermia Enhances the Cytotoxicity of National Institutes of Health 3T3 Cells Transfected with a Noncleavable Transmembrane Pro-Tumor Necrosis Factor Deletion Mutant. Journal of Immunotherapy, 1994, 16, 181-187.	2.4	1
680	THE MICROFOCUS ASSAY SYSTEM (MFAS) - A SIMPLE QUANTITATIVE ASSAY TO IDENTIFY INHIBITORY DRUGS TARGETED AGAINST SPECIFIC ONCOGENES. Oncology Reports, 1994, 1, 37-41.	2.6	1
681	SUPPRESSED AUTOPHOSPHORYLATION AND TYROSINE KINASE-ACTIVITY IN REVERTANT CELL-LINES EXPRESSING RAT NEU ONCOGENE. Oncology Reports, 1994, 1, 895-902.	2.6	0
682	Differential activity of the RVF enhancer element in the decreased expression of theneu oncogene in NR-6 cells versus parental Swiss Webster 3T3 cells. Molecular Carcinogenesis, 1993, 7, 44-49.	2.7	4
683	Repression of neu-induced clonogenicity by dimethylsulfoxide correlates with decreased levels of neu-encoded cell-surface p185 and changes in phosphotyrosine content of endogenous proteins. Cancer Letters, 1993, 68, 55-60.	7.2	0
684	Negative autoregulation of the neu gene is mediated by a novel enhancer.. Molecular and Cellular Biology, 1992, 12, 2739-2748.	2.3	27

#	Article	IF	Citations
685	Differential expression of the neu oncogene in mouse liver and pancreatic cell lines. Biochemical and Biophysical Research Communications, 1992, 186, 363-370.	2.1	2
686	The role of amino functions in recombinant human tumor necrosis factor in expression of biological activity. Molecular Immunology, 1992, 29, 77-81.	2.2	9
687	Oral cancer progression and c-erbB-2/neu proto-oncogene expression. Cancer Letters, 1992, 65, 215-220.	7.2	66
688	Aberrant expression of the c-erbB-2/neu protooncogene in ovarian cancer. Cancer Letters, 1992, 61, 95-103.	7.2	74
689	Overexpression of the c-erbB-2/neuâ€“encoded p185 protein in primary lung cancer. Molecular Carcinogenesis, 1992, 5, 213-218.	2.7	114
690	Adenovirus type 5 E1A gene products act as transformation suppressors of the neu oncogene.. Molecular and Cellular Biology, 1991, 11, 1745-1750.	2.3	90
691	Identification and characterization of a novel enhancer for the rat neu promoter.. Molecular and Cellular Biology, 1991, 11, 1875-1882.	2.3	26
692	c-myc reverses neu-induced transformed morphology by transcriptional repression.. Molecular and Cellular Biology, 1991, 11, 354-362.	2.3	62
693	Multiple cis- and trans-acting elements involved in regulation of the neu gene.. Molecular and Cellular Biology, 1990, 10, 6306-6315.	2.3	55
694	Amplification and expression of the câ€‹erb Bâ€2/neu protoâ€oncogene in human bladder cancer. Molecular Carcinogenesis, 1990, 3, 254-257.	2.7	104
695	Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 4499-4503.	7.1	142
696	A novel alteration in the epidermal growth factor receptor gene is frequently detected in human non-small cell lung cancer. Lung Cancer, 1990, 6, 65-72.	2.0	3
697	Differential Amplification of the TGF-Î± Gene in Human Gliomas. European Journal of Implant and Refractive Surgery, 1990, 2, 201-205.	0.3	36
698	Amplification of the proto-neu oncogene facilitates oncogenic activation by a single point mutation.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 2545-2548.	7.1	45
699	Characterization of rodent epidermal growth factor receptor transcripts using a mouse genomic probe. Biochemical and Biophysical Research Communications, 1986, 141, 1109-1115.	2.1	23
700	Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell, 1986, 45, 649-657.	28.9	1,034
701	Molecular cloning of the neu gene: absence of gross structural alteration in oncogenic alleles.. Proceedings of the National Academy of Sciences of the United States of America, 1986, 83, 261-264.	7.1	155
702	The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature, 1986, 319, 226-230.	27.8	1,090

#	Article	IF	Citations
703	Independent control elements that determine yolk protein gene expression in alternative Drosophila tissues.. Proceedings of the National Academy of Sciences of the United States of America, 1985, 82, 1396-1400.	7.1	168
704	The neu Gene: an erb B-Homologous Gene Distinct from and Unlinked to the Gene Encoding the EGF Receptor. Science, 1985, 229, 976-978.	12.6	490
705	Developmental Control of Drosophila Yolk Protein 1 Gene by cis-acting DNA Elements. Cold Spring Harbor Symposia on Quantitative Biology, 1985, 50, 521-526.	1.1	26
706	Different restriction enzyme-generated sticky DNA ends can be joinedin vitro. Nucleic Acids Research, 1984, 12, 1863-1874.	14.5	40
707	Sequence and structure conservation in yolk proteins and their genes. Journal of Molecular Biology, 1983, 164, 481-492.	4.2	116
708	Transcript maps of Drosophila yolk protein genes. Journal of Molecular Biology, 1982, 154, 581-602.	4.2	40
709	Role of aromatic residues in the structure-function relationship of .alpha.-bungarotoxin. Biochemistry, 1982, 21, 2592-2600.	2.5	30
710	The sequence of the Drosophila melanogaster gene for yolk protein 1. Nucleic Acids Research, 1981, 9, 6407-6419.	14.5	70
711	The status of tyrosyl residues in a Formosan cobra cardiotoxin. Biochimica Et Biophysica Acta (BBA) - Protein Structure, 1978, 535, 178-187.	1.7	13
712	Renaturation of a reduced Taiwan cobra cardiotoxin. Biochimica Et Biophysica Acta (BBA) - Protein Structure, 1978, 533, 105-111.	1.7	5
713	CONFORMATIONAL STABILITY OF A SNAKE CARDIOTOXIN. International Journal of Peptide and Protein Research, 1977, 10, 277-285.	0.1	21